<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cas16339" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2682</journal-id><journal-id journal-id-type="pmc-domain">cas</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11611771</article-id><article-id pub-id-type="pmcid-ver">PMC11611771.1</article-id><article-id pub-id-type="pmcaid">11611771</article-id><article-id pub-id-type="pmcaiid">11611771</article-id><article-id pub-id-type="pmid">39375938</article-id><article-id pub-id-type="doi">10.1111/cas.16339</article-id><article-id pub-id-type="publisher-id">CAS16339</article-id><article-id pub-id-type="other">CAS-OA-2276-2023.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>ORIGINAL ARTICLE</subject><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Genomic and transcriptomic profiling of pre&#8208; and postneoadjuvant chemotherapy triple negative breast cancer tumors</article-title><alt-title alt-title-type="left-running-head">Nishimura et&#160;al.</alt-title></title-group><contrib-group><contrib id="cas16339-cr-0001" contrib-type="author"><name name-style="western"><surname>Nishimura</surname><given-names initials="T">Tomomi</given-names></name><xref rid="cas16339-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cas16339-cr-0002" contrib-type="author"><name name-style="western"><surname>Velaga</surname><given-names initials="R">Ravi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-5962-0266</contrib-id><xref rid="cas16339-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cas16339-cr-0003" contrib-type="author"><name name-style="western"><surname>Masuda</surname><given-names initials="N">Norikazu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7302-0278</contrib-id><xref rid="cas16339-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cas16339-cr-0004" contrib-type="author"><name name-style="western"><surname>Kawaguchi</surname><given-names initials="K">Kosuke</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3161-7981</contrib-id><xref rid="cas16339-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cas16339-cr-0005" contrib-type="author"><name name-style="western"><surname>Kawaguchi</surname><given-names initials="S">Shuji</given-names></name><xref rid="cas16339-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cas16339-cr-0006" contrib-type="author"><name name-style="western"><surname>Takada</surname><given-names initials="M">Masahiro</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5954-1296</contrib-id><xref rid="cas16339-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cas16339-cr-0007" contrib-type="author"><name name-style="western"><surname>Maeshima</surname><given-names initials="Y">Yurina</given-names></name><xref rid="cas16339-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cas16339-cr-0008" contrib-type="author"><name name-style="western"><surname>Tanaka</surname><given-names initials="S">Sunao</given-names></name><xref rid="cas16339-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cas16339-cr-0009" contrib-type="author"><name name-style="western"><surname>Kikawa</surname><given-names initials="Y">Yuichiro</given-names></name><xref rid="cas16339-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="cas16339-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="cas16339-cr-0010" contrib-type="author"><name name-style="western"><surname>Kadoya</surname><given-names initials="T">Takayuki</given-names></name><xref rid="cas16339-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="cas16339-cr-0011" contrib-type="author"><name name-style="western"><surname>Bando</surname><given-names initials="H">Hiroko</given-names></name><xref rid="cas16339-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="cas16339-cr-0012" contrib-type="author"><name name-style="western"><surname>Nakamura</surname><given-names initials="R">Rikiya</given-names></name><xref rid="cas16339-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="cas16339-cr-0013" contrib-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names initials="Y">Yutaka</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6147-6828</contrib-id><xref rid="cas16339-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="cas16339-cr-0014" contrib-type="author"><name name-style="western"><surname>Ueno</surname><given-names initials="T">Takayuki</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9080-9377</contrib-id><xref rid="cas16339-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="cas16339-cr-0015" contrib-type="author"><name name-style="western"><surname>Yasojima</surname><given-names initials="H">Hiroyuki</given-names></name><xref rid="cas16339-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="cas16339-cr-0016" contrib-type="author"><name name-style="western"><surname>Ishiguro</surname><given-names initials="H">Hiroshi</given-names></name><xref rid="cas16339-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="cas16339-cr-0017" contrib-type="author"><name name-style="western"><surname>Morita</surname><given-names initials="S">Satoshi</given-names></name><xref rid="cas16339-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="cas16339-cr-0018" contrib-type="author"><name name-style="western"><surname>Ohno</surname><given-names initials="S">Shinji</given-names></name><xref rid="cas16339-aff-0011" ref-type="aff">
<sup>11</sup>
</xref><xref rid="cas16339-aff-0015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib id="cas16339-cr-0019" contrib-type="author"><name name-style="western"><surname>Haga</surname><given-names initials="H">Hironori</given-names></name><xref rid="cas16339-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="cas16339-cr-0020" contrib-type="author"><name name-style="western"><surname>Matsuda</surname><given-names initials="F">Fumihiko</given-names></name><xref rid="cas16339-aff-0017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib id="cas16339-cr-0021" contrib-type="author"><name name-style="western"><surname>Ogawa</surname><given-names initials="S">Seishi</given-names></name><xref rid="cas16339-aff-0018" ref-type="aff">
<sup>18</sup>
</xref><xref rid="cas16339-aff-0019" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib id="cas16339-cr-0022" contrib-type="author" corresp="yes"><name name-style="western"><surname>Toi</surname><given-names initials="M">Masakazu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1488-9958</contrib-id><xref rid="cas16339-aff-0020" ref-type="aff">
<sup>20</sup>
</xref><address><email>masakazu_toi@tmhp.jp</email></address></contrib></contrib-group><aff id="cas16339-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Next&#8208;generation Clinical Genomic Medicine, Graduate School of Medicine</named-content>
<institution>Kyoto University</institution>
<city>Kyoto</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Breast and Endocrine Surgery</named-content>
<institution>Nagoya University Graduate School of Medicine</institution>
<city>Nagoya</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Breast Surgery</named-content>
<institution>Kyoto University Hospital, Kyoto University</institution>
<city>Kyoto</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Center for Genomic Medicine, Graduate School of Medicine</named-content>
<institution>Kyoto University</institution>
<city>Kyoto</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Breast Surgery</named-content>
<institution>Kobe City Medical Center General Hospital</institution>
<city>Kobe</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Breast Surgery</named-content>
<institution>Kansai Medical University Hospital</institution>
<city>Hirakata</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Breast Center</named-content>
<institution>Shimane University Hospital</institution>
<city>Izumo</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Breast and Endocrine Surgery, Faculty of Medicine</named-content>
<institution>University of Tsukuba</institution>
<city>Tsukuba</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Breast Surgery</named-content>
<institution>Chiba Cancer Center</institution>
<city>Chiba</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Breast and Endocrine Surgery</named-content>
<institution>Kumamoto University, Graduate School of Medical Sciences</institution>
<city>Kumamoto</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Breast Oncology Center</named-content>
<institution>The Cancer Institute Hospital of JFCR</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Surgery, Breast Oncology</named-content>
<institution>NHO Osaka National Hospital</institution>
<city>Osaka</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Breast Oncology Service</named-content>
<institution>Saitama Medical University International Medical Center</institution>
<city>Saitama</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Department of Biomedical Statistics and Bioinformatics</named-content>
<institution>Kyoto University Graduate School of Medicine</institution>
<city>Kyoto</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Social Medical Corporation Hakuaikai</named-content>
<institution>Sagara Hospital</institution>
<city>Kagoshima</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0016">
<label>
<sup>16</sup>
</label>
<named-content content-type="organisation-division">Diagnostic Pathology</named-content>
<institution>Kyoto University Hospital</institution>
<city>Kyoto</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0017">
<label>
<sup>17</sup>
</label>
<named-content content-type="organisation-division">Center for Genomic Medicine (Human Biosciences), Graduate School of Medicine</named-content>
<institution>Kyoto University</institution>
<city>Kyoto</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0018">
<label>
<sup>18</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology and Tumor Biology</named-content>
<institution>Institute for the Advanced Study of Human Biology (WPI&#8208;ASHBi), Kyoto University, Graduate School of Medicine</institution>
<city>Kyoto</city>
<country country="JP">Japan</country>
</aff><aff id="cas16339-aff-0019">
<label>
<sup>19</sup>
</label>
<named-content content-type="organisation-division">Department of Molecular Hematology</named-content>
<institution>Karolinska Institute</institution>
<city>Stockholm</city>
<country country="SE">Sweden</country>
</aff><aff id="cas16339-aff-0020">
<label>
<sup>20</sup>
</label>
<named-content content-type="organisation-division">Tokyo Metropolitan Cancer and Infectious Disease Center</named-content>
<institution>Komagome Hospital</institution>
<city>Bunkyo&#8208;ku</city>
<named-content content-type="country-part">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Masakazu Toi, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, 3&#8208;18&#8208;22 Honkomagome, Bunkyo&#8208;ku 113&#8208;8677, Tokyo, Japan.<break/>
Email: <email>masakazu_toi@tmhp.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>115</volume><issue seq="100">12</issue><issue-id pub-id-type="pmc-issue-id">476212</issue-id><issue-id pub-id-type="doi">10.1111/cas.v115.12</issue-id><fpage>3928</fpage><lpage>3942</lpage><history><date date-type="rev-recd"><day>08</day><month>8</month><year>2024</year></date><date date-type="received"><day>15</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>04</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-04 00:25:45.817"><day>04</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Cancer Science</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CAS-115-3928.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CAS-115-3928.pdf"/><abstract><title>Abstract</title><p>Our understanding of neoadjuvant treatment with microtubule inhibitors (MTIs) for triple negative breast cancer (TNBC) remains limited. To advance our understanding of the role of breast cancer driver genes' mutational status with pathological complete response (pCR; ypT0/isypN0) prediction and to identify distinct gene sets for MTIs like eribulin and paclitaxel, we carried out targeted genomic (<italic toggle="no">n</italic>&#8201;=&#8201;50) and whole transcriptomic profiling (<italic toggle="no">n</italic>&#8201;=&#8201;64) of TNBC tumor samples from the Japan Breast Cancer Research Group 22 (JBCRG&#8208;22) clinical trial. Lower <italic toggle="no">PIK3CA</italic>, <italic toggle="no">PTEN</italic>, and <italic toggle="no">HRAS</italic> mutations were found in homologous recombination deficiency (HRD)&#8208;high (HRD score&#8201;&#8805;&#8201;42) tumors with higher pCR rates. When HRD&#8208;high tumors were stratified by tumor <italic toggle="no">BRCA</italic> mutation status, the pCR rates in <italic toggle="no">BRCA2</italic>&#8208;mutated tumors were higher (83% vs. 36%). Transcriptomic profiling of TP53&#8208;positive tumors identified downregulation of <italic toggle="no">FGFR2</italic> (false discovery rate <italic toggle="no">p</italic> value&#8201;=&#8201;2.07e&#8208;7), which was also the only common gene between HRD&#8208;high and &#8208;low tumors with pCR/quasi&#8208;pCR treated with paclitaxel and eribulin combined with carboplatin, respectively. Differential enrichment analysis of the HRD&#8208;high group posttreatment tumors revealed significant correlation (<italic toggle="no">p</italic>&#8201;=&#8201;0.006) of the glycan degradation pathway. <italic toggle="no">FGFR2</italic> expression and the differentially enriched pathways play a role in the response and resistance to MTIs containing carboplatin treatment in TNBC patients.</p></abstract><abstract abstract-type="graphical"><p>Our study hypothesizes <italic toggle="no">FGFR2</italic>'s potential role in response to microtubule inhibitors containing neoadjuvant chemotherapy in TP53 mutated and microtubule genes in homologous recombination deficiency&#8208;high triple negative breast cancer tumors.<boxed-text position="anchor" content-type="graphic" id="cas16339-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CAS-115-3928-g006.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cas16339-kwd-0001">eribulin</kwd><kwd id="cas16339-kwd-0002">FGFR2</kwd><kwd id="cas16339-kwd-0003">HRD</kwd><kwd id="cas16339-kwd-0004">microtubule inhibitor</kwd><kwd id="cas16339-kwd-0005">triple negative breast cancer</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Eisai Co., Ltd</funding-source></award-group></funding-group><counts><fig-count count="7"/><table-count count="3"/><page-count count="15"/><word-count count="8900"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:03.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="CAS16339-cit-2001"><string-name name-style="western"><surname>Nishimura</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Velaga</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Masuda</surname><given-names>N</given-names></string-name>, et al. <article-title>Genomic and transcriptomic profiling of pre&#8208; and postneoadjuvant chemotherapy triple negative breast cancer tumors</article-title>. <source>Cancer Sci</source>. <year>2024</year>;<volume>115</volume>:<fpage>3928</fpage>&#8208;<lpage>3942</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cas.16339</pub-id><pub-id pub-id-type="pmcid">PMC11611771</pub-id><pub-id pub-id-type="pmid">39375938</pub-id></mixed-citation>
</p></notes></front><body id="cas16339-body-0001"><sec id="cas16339-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Triple negative breast cancer (TNBC) is generally more sensitive to cytotoxic chemotherapy than other breast cancer subtypes. Therapeutic responses such as pathological complete response (pCR)<xref rid="cas16339-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="cas16339-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> is known to be a favorable prognostic indicator in TNBC. However, no standard biomarkers for improved treatment methods are available. Identifying the genes involved in the mechanisms underlying tumor biology can assist in improving survival rates in treatment&#8208;resistant TNBC with poor prognosis. Previous studies of TNBC have reported the roles of genomic and transcriptomic mechanisms in driving chemosensitivity and resistance in TNBC subtypes.<xref rid="cas16339-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="cas16339-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="cas16339-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>We recently undertook a randomized phase II clinical trial (UMIN000023162) in TNBC patients<xref rid="cas16339-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> to determine the effects of the microtubule inhibitors paclitaxel and eribulin in combination with carboplatin. Masuda et&#160;al. reported a response benefit of 40%&#8211;60% when TNBC patients treated with paclitaxel or eribulin combined with carboplatin followed by anthracycline were stratified by homologous recombination deficiency (HRD) score.<xref rid="cas16339-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Homologous recombination deficiency of a cell is the inability of a cell to effectively repair DNA double&#8208;strand breaks using the DNA repair pathways. This suggests that the tumors with good and low response based on the HRD stratification and treatment with paclitaxel or eribulin combined with carboplatin could have a distinct genomic and transcriptomic identifies, leading to differential response to treatment. Only a handful of studies in cell lines and TNBC patients have explored the role of paclitaxel and eribulin at a molecular level.<xref rid="cas16339-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="cas16339-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="cas16339-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> These studies identified epithelial&#8211;mesenchymal transition (EMT), CD8<sup>+</sup> T cells, and microtubule hub genes as potential markers.</p><p>In this study, we analyzed paclitaxel or eribulin plus carboplatin&#8208;treated HRD score&#8208;high and &#8208;low TNBC tumors from the Japan Breast Cancer Research Group 22 (JBCRG&#8208;22) clinical trial to identify unique response markers, enriched gene sets, and pathways. To do so, targeted DNA sequencing was carried out to analyze mutations in driver genes, then the association between mutational profiles and the HRD score and/or the therapeutic responses such as pCR<xref rid="cas16339-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="cas16339-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> was evaluated. Differential gene expression analysis followed by gene set and pathway enrichment analysis was also carried out to identify potential response or resistance biomarkers and to determine upstream regulatory mechanisms that are distinct in the JBCRG&#8208;22 cohort.</p></sec><sec sec-type="materials-and-methods" id="cas16339-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec id="cas16339-sec-0003"><label>2.1</label><title>Study cohort and stratification</title><p>To understand the genomic and transcriptomic nature of HRD stratified tumors with varying treatment regimen, we obtained informed consent from all subjects who participated in this study. The study was approved by the Kyoto University ethical committee. Information related to patient stratification and randomization is described in Masuda et&#160;al.<xref rid="cas16339-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Patients were stratified based on the HRD score, germline <italic toggle="yes">BRCA</italic> mutations (g<italic toggle="yes">BRCA</italic>m) and age. Group A are patients aged &lt;65&#8201;years with HRD&#8208;high score (&#8805;42) who received four cycles of paclitaxel plus carboplatin (PC) (A1 group) or eribulin plus carboplatin (EC) (A2 group), followed by four&#8201;cycles of anthracycline. Group B are patients aged &lt;65&#8201;years with HRD&#8208;score&#8201;&lt;42 (HRD&#8208;low) or aged &#8805;65&#8201;years without g<italic toggle="yes">BRCA</italic>m who were given six&#8201;cycles of eribulin plus cyclophosphamide (B1 group) or eribulin plus capecitabine (B2 group). The patient characteristics are shown in Table&#160;<xref rid="cas16339-tbl-0001" ref-type="table">1</xref>. Tumors collected at the time of diagnosis (pretreatment) and surgery (posttreatment) were analyzed in this study.</p><table-wrap position="float" id="cas16339-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Triple negative breast cancer patient characteristics with tumor <italic toggle="no">BRCA</italic> mutation (t<italic toggle="no">BRCA1/2</italic>m) analysis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="bottom" colspan="1">Characteristic</th><th align="left" colspan="4" valign="bottom" rowspan="1">All cases</th><th align="left" rowspan="2" valign="bottom" colspan="1">Targeted sequencing cases</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">A1</th><th align="left" valign="bottom" rowspan="1" colspan="1">A2</th><th align="left" valign="bottom" rowspan="1" colspan="1">B1</th><th align="left" valign="bottom" rowspan="1" colspan="1">B2</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;23)</th><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;22)</th><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;20)</th><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;21)</th><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;50)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="6" valign="top" rowspan="1">Age at secondary registration, years</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (minimum, maximum)</td><td align="left" valign="top" rowspan="1" colspan="1">44.0 (28&#8211;64)</td><td align="left" valign="top" rowspan="1" colspan="1">47.5 (26&#8211;63)</td><td align="left" valign="top" rowspan="1" colspan="1">57.0 (35&#8211;70)</td><td align="left" valign="top" rowspan="1" colspan="1">55.8 (37&#8211;70)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">54.6 (26&#8211;70)</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Age category at secondary registration, years</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;50</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="char" char="." valign="top" rowspan="1" colspan="1">17</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#8805;50</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="char" char="." valign="top" rowspan="1" colspan="1">33</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;65</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="char" char="." valign="top" rowspan="1" colspan="1">42</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">(&#8805;65)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Anthracycline treatment</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="char" char="." valign="top" rowspan="1" colspan="1">30</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">20</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">TNM classification: T (primary lesion)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T1c</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T2</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">36</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T3</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Tumor size (primary lesion), mm</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (minimum, maximum)</td><td align="left" valign="top" rowspan="1" colspan="1">23.0 (13, 60)</td><td align="left" valign="top" rowspan="1" colspan="1">26.5 (13, 64)</td><td align="left" valign="top" rowspan="1" colspan="1">32.5 (12&#8211;70)</td><td align="left" valign="top" rowspan="1" colspan="1">34.0 (12&#8211;92)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">34.5 (12&#8211;92)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;30.5</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">20</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#8805;30.5</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">30</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">TNM classification: N (regional lymph node)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N0</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">27</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N1</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="char" char="." valign="top" rowspan="1" colspan="1">23</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Histological grade (B&amp;R)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="char" char="." valign="top" rowspan="1" colspan="1">12</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="char" char="." valign="top" rowspan="1" colspan="1">32</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">ER status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="char" char="." valign="top" rowspan="1" colspan="1">48</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">PgR status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">50</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">HER2 status (IHC)<xref rid="cas16339-note-0002" ref-type="table-fn">
<sup>&#8224;</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="char" char="." valign="top" rowspan="1" colspan="1">36</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1+</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2+</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">3+</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Ki&#8208;67 index, %</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (minimum, maximum)</td><td align="left" valign="top" rowspan="1" colspan="1">58.00 (20.2, 92.4)</td><td align="left" valign="top" rowspan="1" colspan="1">66.20 (36.4, 89.6)</td><td align="left" valign="top" rowspan="1" colspan="1">51.0 (20&#8211;90.4)</td><td align="left" valign="top" rowspan="1" colspan="1">51.6 (16.2&#8211;82)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">57.3 (16.2&#8211;90.4)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;30.5</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#8805;30.5</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">CpCR ypN0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">HRD score</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;42</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="char" char="." valign="top" rowspan="1" colspan="1">18</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">42&#8211;63</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&gt;63</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1">21</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">t<italic toggle="yes">BRCA</italic>m status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1</italic>m positive<sup>&#8225;</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA2</italic>m positive</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA</italic>m negative</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">43</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Treatment arm</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">A1</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">A2</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">13</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">B1</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">15</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">B2</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">14</td></tr></tbody></table><table-wrap-foot id="cas16339-ntgp-0001"><fn id="cas16339-note-0001"><p>Abbreviations: B&amp;R, the modified Scarff&#8208;Bloom&#8208;Richardson grading system; CpCR, comprehensive pathological complete response; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HRD, homologous recombination deficiency; IHC, immunohistochemistry; NA, not analyzed; PgR, progesterone receptor.</p></fn><fn id="cas16339-note-0002"><label>
<sup>&#8224;</sup>
</label><p>Absence of <italic toggle="yes">ERBB2</italic> amplification in HER2 IHC 2+ tumors was confirmed via in&#160;situ hybridization assay. Deleterious, suspected deleterious, or uncertain in Myriad test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cas16339-sec-0004"><label>2.2</label><title>
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">BRCA</italic>
</styled-content> mutation analysis and <styled-content style="fixed-case" toggle="no">HRD</styled-content> score calculation</title><p>Tumor <italic toggle="yes">BRCA</italic> mutations (t<italic toggle="yes">BRCA</italic>m) and HRD score were measured by Myriad Genetics using DNA extracted from formalin&#8208;fixed paraffin&#8208;embedded (FFPE) tumor tissues. The HRD score is presented as the total sum of telomeric allelic imbalances, large&#8208;scale transitions, and long regions of LOH chromosomal rearrangements.<xref rid="cas16339-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In this study, tumors with &#8220;deleterious,&#8221; or &#8220;suspected deleterious&#8221; variants in <italic toggle="yes">BRCA</italic> were considered as t<italic toggle="yes">BRCA</italic>m&#8208;positive tumors.</p></sec><sec id="cas16339-sec-0005"><label>2.3</label><title>Targeted <styled-content style="fixed-case" toggle="no">DNA</styled-content> sequencing of tumor samples</title><p>Genome sequencing was undertaken at Kyoto University. Tumor DNA was extracted from 58 FFPE specimens of biopsy material before preoperative drug therapy using a GeneRead DNA FFPE Kit (Qiagen), then analyzed by targeted&#8208;capture sequencing of 189 genes associated with breast cancer (Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S1</xref>) using xGen Predesigned Gene Capture Pools (IDT). Genomic DNA (20&#8211;100&#8201;ng) was enriched for target exons by xGen Prism DNA Library Prep Kit (IDT), and the captured libraries were then sequenced on a DNBSEQ&#8208;G400RS (MGITech) in 150&#8201;bp paired&#8208;end mode. Mutation calling was carried out using the Genomon2 pipeline (version 2.6; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/Genomon-Project" ext-link-type="uri">https://github.com/Genomon&#8208;Project</ext-link>), as previously described.<xref rid="cas16339-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="cas16339-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Following the removal of sequencing errors and single nucleotide polymorphisms, mutations in 28 driver genes reported in a previous study<xref rid="cas16339-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> and hotspot mutations reported in the COSMIC database tumors were considered driver mutations. After excluding poor quality samples, 50 samples for their breast cancer driver mutation profiles were included in the correlation analysis with the pCR and HRD score. Additional information can be found in the Appendix&#160;<xref rid="cas16339-supitem-0001" ref-type="supplementary-material">S1</xref>, section&#160;2.1.</p></sec><sec id="cas16339-sec-0006"><label>2.4</label><title>Tumor <styled-content style="fixed-case" toggle="no">
<italic toggle="no">BRCA</italic>
</styled-content> mutation calling</title><p>As for the analysis of t<italic toggle="yes">BRCA</italic>m by targeted sequencing, mutations with variant allele frequency &#8805;0.4 were considered germline variant candidates. Truncating mutations (nonsense mutations or frameshift indels) and missense, synonymous, and splice&#8208;site mutations registered as &#8220;pathogenic&#8221; or &#8220;likely pathogenic&#8221; in ClinVar (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>)<xref rid="cas16339-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="cas16339-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> were considered pathogenic and t<italic toggle="yes">BRCA</italic>m positive. In case of any discrepancy in t<italic toggle="yes">BRCA</italic>m statuses between the Myriad analysis and targeted sequencing, the t<italic toggle="yes">BRCA</italic>m status determined by Myriad was utilized. Additional information about the variant status can be found in Appendix&#160;<xref rid="cas16339-supitem-0001" ref-type="supplementary-material">S1</xref>, section&#160;2.11 and Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S2</xref>.</p></sec><sec id="cas16339-sec-0007"><label>2.5</label><title>Tumor response assessment</title><p>The tumor response after the initial phase of chemotherapy, which consisted of paclitaxel plus carboplatin or eribulin plus carboplatin (PC or EC, respectively), was assessed by MRI. The largest diameter of the percentage tumor size before and after PC or EC treatment was calculated based on the MRI. The comprehensive pathological complete response (CpCR; ypT0/isypN0) was used as the definition of pCR in this translational study.</p></sec><sec id="cas16339-sec-0008"><label>2.6</label><title>Sample preparation for <styled-content style="fixed-case" toggle="no">RNA</styled-content> sequencing and quality control</title><p>Deparaffinization was undertaken by melting, and RNA isolation from the pre&#8208; and posttreatment FFPE tumor tissue slides was prepared using Qiagen's miRNeasy mini kit standard protocol. RNA isolates were processed using Illumina RNA Prep with Enrichment (L) Tagmentation according to the vendor's instructions. RNA samples were sequenced on a Novaseq S4 2&#8201;&#215;&#8201;75&#8201;bp flow cell by XING Genomic Services. All raw reads from RNA sequencing (RNA&#8208;seq) data were trimmed using Trimmomatic (version 0.36).<xref rid="cas16339-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Reads were aligned and mapped to the human genome reference genome (Homo_sapiens.GRCh38) and transcript reference (Homo_sapiens.GRCh38.84.gtf) using Illumina's DRAGEN (version 07.021.602.3.8.4). The transcripts per million (TPM) count was obtained using TPMcalculator (version 0.0.3)<xref rid="cas16339-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> and unique exons were mapped (Figures&#160;<xref rid="cas16339-supitem-0002" ref-type="supplementary-material">S1</xref> and <xref rid="cas16339-supitem-0002" ref-type="supplementary-material">S2</xref>, Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S3</xref>). After the quality control, 64 transcriptomic profiles were used in the analysis. Additional information about the transcriptomic data processing and quality control can be found in Appendix&#160;<xref rid="cas16339-supitem-0001" ref-type="supplementary-material">S1</xref>, section&#160;2.12.</p></sec><sec id="cas16339-sec-0009"><label>2.7</label><title>Differential gene expression analysis</title><p>Analyses of differential gene expression (DGE) and commonly expressed genes among different comparison groups were carried out using Qiagen CLC Genomics Workbench 20.0.2 and 20.0.4 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://digitalinsights.qiagen.com/" ext-link-type="uri">https://digitalinsights.qiagen.com/</ext-link>).<xref rid="cas16339-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> The different observational groups from the A and B stratified groups considered for DGE and pathway analyses include t<italic toggle="yes">BRCA</italic>m&#8208;positive versus t<italic toggle="yes">BRCA</italic>m&#8208;negative groups, tumors &lt;30.5 versus &#8805;30.5&#8201;mm in size, <italic toggle="yes">TP53</italic> mutation&#8208;positive versus &#8208;negative tumors, <italic toggle="yes">PIK3CA</italic> mutation&#8208;positive versus &#8208;negative tumors, HRD&#8208;high versus HRD&#8208;low, A group pre&#8208; versus posttreatment tumors, A1 posttreatment versus A2 posttreatment tumors, and A group pretreatment versus B group pretreatment tumors can be in found in Appendix&#160;<xref rid="cas16339-supitem-0001" ref-type="supplementary-material">S1</xref>, section&#160;2.13. The TPM values with a minimum count of 1 for the corresponding group were imported to the CLC Genomics Workbench, including a list of 17,098 genes. Unmatched gene IDs were ignored. Differentially expressed genes were identified as genes with <italic toggle="yes">p</italic> value &#8804;0.05 and fold change (FC)&#8201;&#8805;1, and false discovery rate (FDR) less than 5% (0.05) according to the Benjamini&#8211;Hochberg method<xref rid="cas16339-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> in expression among groups.</p></sec><sec id="cas16339-sec-0010"><label>2.8</label><title>Gene set enrichment analysis</title><p>Gene expression values (log<sub>2</sub>FC) from the CLC Genomics Workbench were imported into the Gene Set Enrichment Analysis (GSEA) Preranked tool<xref rid="cas16339-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> to identify gene sets that are differentially enriched among the observational group comparisons as mentioned in section&#160;2.7. GSEA Constellation Map<xref rid="cas16339-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> was used to plot the heatmap and area under curve (AUC) correlation among the observational groups. Based on the enrichment, GSEA results in multiple significantly enriched gene sets, the Constellation Map tool, a gene network&#8208;based tool, assists in interpreting the enrichment results and scores relative to the phenotype. Constellation Map also takes into consideration the density of genes enriched from GSEA and estimate the normalized mutual information (NMI) score to measure the association significance. The TPM values from CLC Genomics Workbench were used as input values to generate the heatmaps and the corresponding AUC correlations. Genes for which the FDR was less than 25% (0.25) and <italic toggle="yes">p</italic> value was less than 0.01 (1%) or 0.05 (5%) were considered when determining the enriched gene sets.</p></sec><sec id="cas16339-sec-0011"><label>2.9</label><title>Pathway and upstream regulatory analysis</title><p>Pathway enrichment and upstream regulatory analyses of samples before and after treatment with TPM values were carried out on the 17,098 genes that were included in the differential expression analysis using Qiagen's Ingenuity Pathway Analysis (IPA) tool.<xref rid="cas16339-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The IPA z score, which is based on the known neighborhood gene activity analysis, predicts the overall activation or inhibition of the pathway or gene. An overall positive z score&#8201;&#8805;2 predicts pathway activation and z score&#8201;&lt;2 predicts the pathway inhibition.</p></sec><sec id="cas16339-sec-0012"><label>2.10</label><title>Statistical analysis</title><p>The significance of the relationships between genomic profiling outcomes, such as t<italic toggle="yes">BRCA</italic>m status, HRD score, presence or absence of driver gene mutations, and pCR as a measure of the therapeutic response was analyzed with Fisher's exact test for comparison of categorical variables and with <italic toggle="yes">t</italic> tests for comparison of continuous variables. These analyses were undertaken with R version 3.6.3 (the GNU Project). Multiple testing was corrected based on the Benjamini&#8211;Hochberg method.<xref rid="cas16339-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> A <italic toggle="yes">p</italic> value less than 0.05 and <italic toggle="yes">q</italic> value less than 0.1 indicated a statistically significant difference.</p></sec></sec><sec sec-type="results" id="cas16339-sec-0013"><label>3</label><title>RESULTS</title><sec id="cas16339-sec-0014"><label>3.1</label><title>Target capture sequencing outcomes</title><p>Following the JBCRG&#8208;22 clinical trial among TNBC subjects with HRD&#8208;high and HRD&#8208;low scores treated with microtubule inhibitors like paclitaxel or eribulin plus carboplatin, this translational research study was undertaken to identify the correlation between the mutational status, treatment response, DEGs, and pathways among the observational groups as described in the above sections.</p></sec><sec id="cas16339-sec-0015"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">TP53</italic>
</styled-content> and <styled-content style="fixed-case" toggle="no">
<italic toggle="no">KMT2C</italic>
</styled-content> mutation&#8208;positive tumors</title><p>A total of 50 TNBC tumors (A1&#8201;=&#8201;8, A2&#8201;=&#8201;13, B1&#8201;=&#8201;15, B2&#8201;=&#8201;14) were analyzed by targeted&#8208;capture sequencing. Mutations were frequently identified in <italic toggle="yes">TP53</italic> (<italic toggle="yes">n</italic>&#8201;=&#8201;36), <italic toggle="yes">PIK3CA</italic> (<italic toggle="yes">n</italic>&#8201;=&#8201;16), <italic toggle="yes">KMT2C</italic> (<italic toggle="yes">n</italic>&#8201;=&#8201;6), and <italic toggle="yes">PTEN</italic> (<italic toggle="yes">n</italic>&#8201;=&#8201;5) (Figure&#160;<xref rid="cas16339-fig-0001" ref-type="fig">1</xref>, Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S4</xref>). Although <italic toggle="yes">TP53</italic> mutations were frequently detected regardless of HRD status, the <italic toggle="yes">PIK3CA</italic> mutation rate was significantly higher in HRD&#8208;low tumors than in HRD&#8208;high tumors (61.1% and 4.8%, respectively [<italic toggle="yes">q</italic> value&#8201;=&#8201;1.3&#8201;&#215;&#8201;10<sup>&#8722;3</sup>]), and the same pattern was found for <italic toggle="yes">PTEN</italic> and <italic toggle="yes">HRAS</italic> (Figure&#160;<xref rid="cas16339-fig-0002" ref-type="fig">2A</xref>). Among tumors with mutations in <italic toggle="yes">TP53</italic> and <italic toggle="yes">KMT2C</italic>, the pCR rate tended to be higher than in tumors without mutations (<italic toggle="yes">TP53</italic>: 25.0% vs. 14.3% [<italic toggle="yes">q</italic> value&#8201;=&#8201;0.88]; <italic toggle="yes">KMT2C</italic>: 50.0% vs. 18.2% [<italic toggle="yes">q</italic> value&#8201;=&#8201;0.56]). However, among tumors with mutations in <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">HRAS</italic>, the pCR rate tended to be lower than in tumors without mutations (<italic toggle="yes">PIK3CA</italic>: 12.5% vs. 26.5% [<italic toggle="yes">q</italic> value&#8201;=&#8201;0.88]; <italic toggle="yes">HRAS</italic>: 0% vs. 23.9% [<italic toggle="yes">q</italic> value&#8201;=&#8201;0.88]) (Figure&#160;<xref rid="cas16339-fig-0002" ref-type="fig">2B</xref>). Higher pCR rate in <italic toggle="yes">TP53</italic> and <italic toggle="yes">KMT2C</italic> mutation&#8208;positive tumors could be a sign of cancer cells failing to repair themselves. This observation led us to evaluate and understand the t<italic toggle="yes">BRCA</italic>m status and its correlation with pCR among the HRD&#8208;high and HRD&#8208;low groups.</p><fig position="float" fig-type="FIGURE" id="cas16339-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Landscape of the mutations detected in triple negative breast cancer tumors by targeted sequencing. The distribution and types of recurrent gene mutations in the tumors are shown. C4, biopsy samples after four cycles of chemotherapy; CR, complete response; HRD, homologous recombination deficiency; NA, not analyzed; ope, surgical samples after chemotherapy; pCR, pathological complete response (ypT0/is+ypN0); PD, progressive disease; PR, partial response; pre, biopsy samples before chemotherapy; SD, stable disease; SNV, single nucleotide variant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CAS-115-3928-g005.jpg"/></fig><fig position="float" fig-type="FIGURE" id="cas16339-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Correlations between tumor mutation profile, homologous recombination deficiency (HRD) score, and comprehensive pathological complete response (pCR), indicated by ypT0/is+ypN0, in triple negative breast cancer. (A) Mutation rate of recurrently mutated genes in HRD&#8208;positive (score &#8805;42) cases (groups A1 [<italic toggle="yes">n</italic>&#8201;=&#8201;8] and A2 [<italic toggle="yes">n</italic>&#8201;=&#8201;13]) and HRD&#8208;negative (score &lt;42) cases (groups B1 [<italic toggle="yes">n</italic>&#8201;=&#8201;10] and B2 [<italic toggle="yes">n</italic>&#8201;=&#8201;8]), in which both the Myriad HRD test and targeted sequencing were successfully carried out. (B) pCR rates in cases with mutations in each recurrently mutated gene. The case number corresponding to each bar has been added to the bar chart, with <italic toggle="yes">q</italic> values (<italic toggle="yes">q</italic>) from two&#8208;sided Fisher's exact test with Benjamini&#8211;Hochberg adjustment. *Significant difference (<italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.1).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CAS-115-3928-g001.jpg"/></fig></sec><sec id="cas16339-sec-0016"><label>3.3</label><title>
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">BRCA</italic>
</styled-content> mutational status, <styled-content style="fixed-case" toggle="no">HRD</styled-content> score, and correlation with <styled-content style="fixed-case" toggle="no">pCR</styled-content>
</title><p>Understanding the correlation between the HRD score and t<italic toggle="yes">BRCA</italic>m status could help assess the tumor's ability to repair DNA damage and could guide treatment decisions. Our analysis showed that HRD scores were significantly higher in t<italic toggle="yes">BRCA</italic>m&#8208;positive cases than in t<italic toggle="yes">BRCA</italic>m&#8208;negative cases. Median HRD scores were 64 (range, 45&#8211;76) and 21 (range, 2&#8211;73) in t<italic toggle="yes">BRCA</italic>m&#8208;positive and t<italic toggle="yes">BRCA</italic>m&#8208;negative cases, respectively (<italic toggle="yes">p</italic> value&#8201;=&#8201;6.7&#8201;&#215;&#8201;10<sup>&#8722;4</sup>) (Figure&#160;<xref rid="cas16339-fig-0003" ref-type="fig">3A</xref>, Table&#160;<xref rid="cas16339-tbl-0002" ref-type="table">2A</xref>), and HRD scores were significantly correlated with CpCR (ypT0/is+ypN0) (Figures&#160;<xref rid="cas16339-fig-0003" ref-type="fig">3B</xref> and <xref rid="cas16339-supitem-0002" ref-type="supplementary-material">S3</xref>, Table&#160;<xref rid="cas16339-tbl-0002" ref-type="table">2</xref>, Appendix&#160;<xref rid="cas16339-supitem-0001" ref-type="supplementary-material">S1</xref>, section&#160;3.2). We also investigated the potential role of t<italic toggle="yes">BRCA</italic>m in the treatment response. All the t<italic toggle="yes">BRCA</italic>m&#8208;positive tumors were HRD&#8208;high and came from the groups that received a carboplatin&#8208;containing regimen PC or EC followed by anthracycline&#8208;based regimen (A1 or A2 group). In the A1 group, the pCR rates were 66.7% (4/6), 100% (3/3), and 57.1% (8/14) in the t<italic toggle="yes">BRCA1</italic>m&#8208;positive, t<italic toggle="yes">BRCA2</italic>m&#8208;positive, and t<italic toggle="yes">BRCA</italic>m&#8208;negative subgroups, respectively (Table&#160;<xref rid="cas16339-tbl-0002" ref-type="table">2</xref>). In the A2 group, the pCR rates were 0% (0/5) in the t<italic toggle="yes">BRCA1</italic>m&#8208;positive subgroup, 66.7% (2/3) in the t<italic toggle="yes">BRCA2</italic>m&#8208;positive subgroup, and 57.1% (16/28) in the t<italic toggle="yes">BRCA</italic>m&#8208;negative subgroups (Table&#160;<xref rid="cas16339-tbl-0002" ref-type="table">2B</xref>).</p><fig position="float" fig-type="FIGURE" id="cas16339-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Correlations between the homologous recombination deficiency (HRD) score, comprehensive pathological complete response (pCR), and tumor <italic toggle="yes">BRCA</italic> mutation (t<italic toggle="yes">BRCA1/2</italic>m) status in triple negative breast cancer. The correlation between pCR and t<italic toggle="yes">BRCA1/2</italic>m status was analyzed in 74/78 (94.9%) Myriad&#8208;tested cases in which the HRD score was successfully determined. (A) Correlation between t<italic toggle="yes">BRCA</italic>m status and HRD score.(B) Correlation between the HRD score and comprehensive pCR as ypT0/is&#8201;+&#8201;ypN0.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="CAS-115-3928-g007.jpg"/></fig><table-wrap position="float" id="cas16339-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Relationship between homologous recombination deficiency (HRD) score and comprehensive pathological complete response (pCR; indicated by ypT0/is&#8201;+&#8201;ypN0) in patients with triple negative breast cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="6" valign="bottom" rowspan="1">(A) Comprehensive pCR in HRD&#8208;positive and &#8208;negative groups</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" colspan="2" valign="bottom" rowspan="1">pCR rate, (%) (<italic toggle="yes">n</italic>/<italic toggle="yes">N</italic>)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> &#8208;value</th><th align="left" valign="bottom" rowspan="1" colspan="1"/></tr></thead><tbody valign="top"><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>HRD positive (HRD score&#8201;&#8805;&#8201;&#8201;&gt;&#8201;=&#8201;42)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>55.6</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>(25/45)</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>0.003805</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A1</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">65.2</td><td align="left" valign="top" rowspan="1" colspan="1">(15/23)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1</italic>m positive</td><td align="left" valign="top" rowspan="1" colspan="1">66.7</td><td align="left" valign="top" rowspan="1" colspan="1">(4/6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA2</italic>m <italic toggle="yes">positive</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">100</td><td align="left" valign="top" rowspan="1" colspan="1">(3/3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1/2</italic>&#8201;m negative</td><td align="left" valign="top" rowspan="1" colspan="1">57.1</td><td align="left" valign="top" rowspan="1" colspan="1">(8/14)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A2</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">45.5</td><td align="left" valign="top" rowspan="1" colspan="1">(10/22)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1</italic>m positive</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0/5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA2</italic>m <italic toggle="yes">positive</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">66.7</td><td align="left" valign="top" rowspan="1" colspan="1">(2/3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1/2</italic>&#8201;m negative</td><td align="left" valign="top" rowspan="1" colspan="1">57.1</td><td align="left" valign="top" rowspan="1" colspan="1">(8/14)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>HRD negative (HRD score&#8201;&lt;&#8201;42)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>20.7</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>(6/29)</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">B1</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">7.1</td><td align="left" valign="top" rowspan="1" colspan="1">(1/14)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1</italic>m positive</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;&#8208;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA2</italic>m <italic toggle="yes">positive</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;&#8208;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1/2</italic>&#8201;m negative</td><td align="left" valign="top" rowspan="1" colspan="1">7.1</td><td align="left" valign="top" rowspan="1" colspan="1">(1/14)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">B2</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">33.3</td><td align="left" valign="top" rowspan="1" colspan="1">(5/15)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1</italic>m positive</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;&#8208;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA2</italic>m <italic toggle="yes">positive</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;&#8208;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1/2</italic>&#8201;m negative</td><td align="left" valign="top" rowspan="1" colspan="1">33.3</td><td align="left" valign="top" rowspan="1" colspan="1">(5/15)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">41.9</td><td align="left" valign="top" rowspan="1" colspan="1">(31/74)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="6" valign="bottom" rowspan="1">(B) Comprehensive pCR in HRD&#8208;positive (A1 and A2) treatment groups by t<italic toggle="yes">BRCA</italic>m status</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">A1</th><th align="left" valign="bottom" rowspan="1" colspan="1">A2</th><th align="left" valign="bottom" rowspan="1" colspan="1">Total, <italic toggle="yes">n</italic>/<italic toggle="yes">N</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">&#967;<sup>2</sup>&#8208;test, Pearson</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">tBRCA1m positive</td><td align="left" valign="top" rowspan="1" colspan="1">4/6</td><td align="left" valign="top" rowspan="1" colspan="1">0/5</td><td align="left" valign="top" rowspan="1" colspan="1">4/11 (36.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5.238</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>0.0221</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA2</italic>m <italic toggle="yes">positive</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">3/3</td><td align="left" valign="top" rowspan="1" colspan="1">2/3</td><td align="left" valign="top" rowspan="1" colspan="1">5/6 (83.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.200</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.2730</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1/2</italic>&#8201;m negative</td><td align="left" valign="top" rowspan="1" colspan="1">8/14</td><td align="left" valign="top" rowspan="1" colspan="1">8/14</td><td align="left" valign="top" rowspan="1" colspan="1">16/28 (57.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.000</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total (%)</td><td align="left" valign="top" rowspan="1" colspan="1">15/23 (65.2)</td><td align="left" valign="top" rowspan="1" colspan="1">10/22 (45.5)</td><td align="left" valign="top" rowspan="1" colspan="1">25/45 (55.6)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#967;<sup>2</sup>&#8208;test, Pearson</td><td align="left" valign="top" rowspan="1" colspan="1">2.008</td><td align="left" valign="top" rowspan="1" colspan="1">7.376</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</td><td align="left" valign="top" rowspan="1" colspan="1">0.366</td><td align="left" valign="top" rowspan="1" colspan="1">0.0645</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cas16339-ntgp-0002"><fn id="cas16339-note-0003"><p>
<italic toggle="yes">Note</italic>: Tumor <italic toggle="yes">BRCA</italic> mutation (tBRCAm) status, A1/A2, and pCR: &#967;<sup>2</sup>&#8208;test, 5.877; <italic toggle="yes">p</italic> value&#8201;=&#8201;0.117. Bold <italic toggle="yes">p</italic> values&#8201;&#8804;&#8201;0.05 were considered to be significant.</p></fn></table-wrap-foot></table-wrap><p>While the regimen consisting of PC followed by anthracycline (PC&#8208;A) regimen (A1 group) achieved pCR rates of over 60% in both t<italic toggle="yes">BRCA1</italic>m&#8208; and t<italic toggle="yes">BRCA2</italic>m&#8208;positive groups, EC followed by anthracycline (EC&#8208;A) (A2 group) resulted in a high pCR rate in the t<italic toggle="yes">BRCA2</italic>m&#8208;positive subgroup only (Tables&#160;<xref rid="cas16339-tbl-0001" ref-type="table">1</xref>, <xref rid="cas16339-tbl-0002" ref-type="table">2</xref>, <xref rid="cas16339-tbl-0003" ref-type="table">3</xref>).</p><p>When stratified by t<italic toggle="yes">BRCA1</italic>m and t<italic toggle="yes">BRCA2</italic>m, the pCR rates of t<italic toggle="yes">BRCA2</italic>m tumors were markedly higher than those of t<italic toggle="yes">BRCA1</italic>m tumors (83% vs. 36%) (Table&#160;<xref rid="cas16339-tbl-0002" ref-type="table">2B</xref>). For t<italic toggle="yes">BRCA</italic>m&#8208; negative TNBC with high HRD scores, the PC&#8208;A and EC&#8208;A regimens produced pCR rates that were not significantly different (Table&#160;<xref rid="cas16339-tbl-0002" ref-type="table">2B</xref>). Mutational analysis revealed that two of the six tumors in the A2 treatment group with no response to the treatment had a pathogenic variant in <italic toggle="yes">BRCA1</italic> at c.188&#8201;T&#8201;&gt;&#8201;A (p.Leu63*/L63X) (Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S4</xref>). Other tumors showed pathogenic variants in <italic toggle="yes">BRCA1</italic> at c.1827del (p.Asn609Lysfs*3), c.2021C&#8201;&gt;&#8201;T (p.Pro674Leu), and c.3640G&#8201;&gt;&#8201;T (p.Glu1214*). These observations suggest that the type of <italic toggle="yes">BRCA</italic> mutation and treatment regimen might influence tumor response to chemotherapy. Following this finding, we examined the t<italic toggle="yes">BRCA</italic>m&#8208;positive tumors for a unique set of DEGs and pathways.</p></sec><sec id="cas16339-sec-0017"><label>3.4</label><title>Differential gene expression and pathway analysis in <styled-content style="fixed-case" toggle="no">t<italic toggle="no">BRCA</italic>m</styled-content>&#8208;positive tumors and role of tumor size</title><p>To further elucidate the molecular mechanisms in t<italic toggle="yes">BRCA</italic>m&#8208;positive versus t<italic toggle="yes">BRCA</italic>m&#8208;negative tumors, we undertook differential gene and pathway analyses. We analyzed the DEGs between pretreatment t<italic toggle="yes">BRCA</italic>m&#8208;positive (<italic toggle="yes">n</italic>&#8201;=&#8201;13) and t<italic toggle="yes">BRCA</italic>m&#8208;negative (<italic toggle="yes">n</italic>&#8201;=&#8201;24) samples (Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S5</xref>). We found that six genes were upregulated and five genes were downregulated in the t<italic toggle="yes">BRCA</italic>m&#8208;positive cohort with FDR <italic toggle="yes">p</italic> value &lt;0.05 (Figure&#160;<xref rid="cas16339-fig-0004" ref-type="fig">4A</xref>, Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S5</xref>). Transcriptomic profiling based on tumor size revealed 944 genes to be differentially expressed between tumors &lt;30.5 versus &#8805;30.5&#8201;mm in size (<italic toggle="yes">n</italic>&#8201;=&#8201;24 vs. 25). Among these genes, 861 genes were found to be upregulated and 83 genes to be downregulated in the tumors with a size &#8805;30.5&#8201;mm at FDR <italic toggle="yes">p</italic> value &lt;0.05 (Figure&#160;<xref rid="cas16339-fig-0004" ref-type="fig">4B</xref>, Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S6</xref>). Differential enrichment cancer hallmark gene sets were identified between t<italic toggle="yes">BRCA</italic>m&#8208;positive versus t<italic toggle="yes">BRCA</italic>m&#8208;negative tumors (Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S7</xref>). While detecting the relevant gene sets in tumors with &lt;30.5 versus &#8805;30.5&#8201;mm in size, t<italic toggle="yes">BRCA</italic>m status was not taken into consideration (Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S8</xref>). Identifying these DEGs, such as <italic toggle="yes">DLK1</italic> and <italic toggle="yes">FGFR2</italic> with significant differential expression and enriched pathways, points to the role these significantly differentially expressed genes and of cancer hallmark gene sets like TNFA, EMT, and p53 pathways in the t<italic toggle="yes">BRCA</italic>m&#8208;positive group that could serve as potential biomarkers for personalized treatment strategies.</p><fig position="float" fig-type="FIGURE" id="cas16339-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Differential expression analysis of genes in triple negative breast cancer tumors with different characteristics, depicted as volcano plots. (A) <italic toggle="yes">BRCA1/2</italic>&#8208;mutated (pos) versus &#8208;negative (neg) tumors in groups A and B. (B) Tumor size &lt;30.5 versus &#8805;30.5&#8201;mm (<italic toggle="yes">n</italic>&#8201;=&#8201;24 vs. 25) in groups A and B. (C) <italic toggle="yes">TP53</italic>&#8208;mutated versus &#8208;negative (<italic toggle="yes">n</italic>&#8201;=&#8201;22 vs. 34) tumors in groups A and B. (D) <italic toggle="yes">PIK3CA</italic>&#8208;mutated versus &#8208;negative (<italic toggle="yes">n</italic>&#8201;=&#8201;7 vs. 42) tumors in groups A and B. (E) Homologous recombination deficiency (HRD)&#8208;high versus HRD&#8208;low (<italic toggle="yes">n</italic>&#8201;=&#8201;27 vs. 9) tumors in groups A and B. (F) Pre&#8208; and posttreatment (<italic toggle="yes">n</italic>&#8201;=&#8201;11 vs. 10) tumors from patients in group A without a pathological complete response (NpCR), (G) pre&#8208; and posttreatment tumors (<italic toggle="yes">n</italic>&#8201;=&#8201;3 vs. 3) from patients in group A1 classified as NpCR. (H) Pre&#8208; and posttreatment (<italic toggle="yes">n</italic>&#8201;=&#8201;8 vs. 7) tumors from patients in group A2 classified as NpCR. (I) Pretreatment tumors from patients in group A who achieved a pathological complete response (pCR) (1) and those that did not (0) (<italic toggle="yes">n</italic>&#8201;=&#8201;16 vs. 11).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="CAS-115-3928-g003.jpg"/></fig></sec><sec id="cas16339-sec-0018"><label>3.5</label><title>Transcriptomic profiling of tumors with <styled-content style="fixed-case" toggle="no">
<italic toggle="no">TP53</italic>
</styled-content> and <styled-content style="fixed-case" toggle="no">
<italic toggle="no">PIK3CA</italic>
</styled-content> mutations</title><p>Irrespective of t<italic toggle="yes">BRCA</italic>m status, identifying uniquely enriched gene sets in <italic toggle="yes">TP53</italic> and <italic toggle="yes">PIK3CA</italic> mutation&#8208;positive tumors could improve our understanding of the nature of tumor response/resistance and cancer progression. Differential gene expression analysis between <italic toggle="yes">TP53</italic> mutation&#8208;positive (<italic toggle="yes">n</italic>&#8201;=&#8201;22) and &#8208;negative (<italic toggle="yes">n</italic>&#8201;=&#8201;34) tumors revealed that <italic toggle="yes">TP53</italic> mutation&#8208;positive tumors showed downregulated FGFR2 expression with an FDR <italic toggle="yes">p</italic> value of 2.07&#8201;&#215;&#8201;10<sup>&#8722;7</sup>, while FRA10AC1 and PSPH were upregulated with FDR <italic toggle="yes">p</italic> values of 2.07&#8201;&#215;&#8201;10<sup>&#8722;7</sup> and 4.35&#8201;&#215;&#8201;10<sup>&#8722;3</sup>, respectively (Figure&#160;<xref rid="cas16339-fig-0004" ref-type="fig">4C</xref>, Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S9</xref>). A similar analysis of <italic toggle="yes">PIK3CA</italic> mutation&#8208;positive (<italic toggle="yes">n</italic>&#8201;=&#8201;7) and &#8208;negative (<italic toggle="yes">n</italic>&#8201;=&#8201;42) samples revealed 28,265 downregulated genes, including <italic toggle="yes">FGFR2</italic>, and 32 upregulated genes in <italic toggle="yes">PIK3CA</italic> mutation&#8208;positive tumors (<italic toggle="yes">n</italic>&#8201;=&#8201;266), according to an FDR <italic toggle="yes">p</italic> value &lt;0.05 (Figure&#160;<xref rid="cas16339-fig-0004" ref-type="fig">4D</xref>, Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S10</xref>). It is known that when FGFR2 dysregulated and <italic toggle="yes">TP53</italic> mutation is positive, it can lead to improved cancer cell survival.<xref rid="cas16339-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> It would be interesting to further evaluate <italic toggle="yes">TP53</italic> mutation&#8208;positive tumors, with differentially expressed FGFR2.</p></sec><sec id="cas16339-sec-0019"><label>3.6</label><title>Differential gene expression and pathway analysis of <styled-content style="fixed-case" toggle="no">HRD</styled-content>&#8208;high and <styled-content style="fixed-case" toggle="no">HRD</styled-content>&#8208;low groups</title><p>As the HRD score was used as a molecular marker to stratify patients in the JBCRG&#8208;22 clinical trial, we identified DEGs and differentially activated pathways in pretreatment tumors between the HRD&#8208;high, which includes both A1 and A2 subgroups (A group, <italic toggle="yes">n</italic>&#8201;=&#8201;27), and HRD&#8208;low groups, which includes both B1 and B2 groups (B group, <italic toggle="yes">n</italic>&#8201;=&#8201;9), using the transcriptomic profiles that passed quality control. Differential gene expression analysis revealed 806 DEGs, including 636 upregulated and 170 downregulated genes (Figure&#160;<xref rid="cas16339-fig-0004" ref-type="fig">4E</xref>), with an FDR <italic toggle="yes">p</italic> value &lt;0.05 in the pretreatment A group (HRD high) compared to the pretreatment B group (HRD low) (Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S11</xref>). Further analysis of the association of different microtubule genes can be found in Appendix&#160;<xref rid="cas16339-supitem-0001" ref-type="supplementary-material">S1</xref>, section&#160;3.3 with relevant supporting figure (Figure&#160;<xref rid="cas16339-supitem-0002" ref-type="supplementary-material">S5</xref>) and table (Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S21</xref>).</p></sec><sec id="cas16339-sec-0020"><label>3.7</label><title>Differential gene expression and pathway analyses of the A group with and without <styled-content style="fixed-case" toggle="no">pCR</styled-content> (pretreatment vs. posttreatment)</title><p>Gene expression levels from the patient RNA&#8208;seq profiles were used to identify differentially expressed gene sets before (<italic toggle="yes">n</italic>&#8201;=&#8201;11) and after (<italic toggle="yes">n</italic>&#8201;=&#8201;10) treatment in samples from the A group. A total of 309 and 57 genes were found to be significantly upregulated and downregulated, respectively, in the posttreatment group (FDR <italic toggle="yes">p</italic> value &lt;0.05) compared to the pretreatment samples in the A group without pCR (Figure&#160;<xref rid="cas16339-fig-0004" ref-type="fig">4F</xref>, Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S12</xref>). A few common upregulated genes, such as <italic toggle="yes">FOS</italic>, <italic toggle="yes">EGR1</italic>, <italic toggle="yes">PLIN4</italic>, <italic toggle="yes">CD36</italic>, <italic toggle="yes">JUN,</italic> and others (Figure&#160;<xref rid="cas16339-fig-0004" ref-type="fig">4G,H</xref>, Tables&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S13 and S14</xref>), were observed in both the A1 and A2 posttreatment tumors.</p><p>In the group A with pretreatment tumors of patients who achieved pCR (<italic toggle="yes">n</italic>&#8201;=&#8201;16) and those who did not achieve pCR (<italic toggle="yes">n</italic>&#8201;=&#8201;11), the <italic toggle="yes">DLK1</italic> (FDR <italic toggle="yes">p</italic> value&#8201;=&#8201;7.84e&#8208;9) and <italic toggle="yes">FGFR2</italic> (FDR <italic toggle="yes">p</italic> value&#8201;=&#8201;0.01) genes and the <italic toggle="yes">CSN2</italic> (FDR <italic toggle="yes">p</italic> value&#8201;=&#8201;4.43e&#8208;7) and <italic toggle="yes">LALBA</italic> (FDR <italic toggle="yes">p</italic> value&#8201;=&#8201;3.20e&#8208;5) genes were found to be significantly upregulated and downregulated, respectively (Figure&#160;<xref rid="cas16339-fig-0004" ref-type="fig">4I</xref>, Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S15</xref>). The IPA of pretreatment (<italic toggle="yes">n</italic>&#8201;=&#8201;11) and posttreatment (<italic toggle="yes">n</italic>&#8201;=&#8201;10) tumor samples from patients in the A group predicted that the tumor microenvironment pathway, regulation of EMT by growth factors pathway, and FAK, interleukin&#8208;17 (IL&#8208;17), and IL&#8208;6 signaling were activated (z score&#8201;&gt;2.00) in the posttreatment tumors (Figure&#160;<xref rid="cas16339-supitem-0002" ref-type="supplementary-material">S4</xref>, Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S16</xref>). When the posttreatment tumors from the A1 and A2 group tumors were analyzed to further investigate enriched gene sets using GSEA Constellation Map, it revealed a significant correlation with KEGG_OTHER_GLYCAN_DEGRADATION with a significant <italic toggle="yes">p</italic> value of 0.006 and AUC 0.9 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.009) (Figure&#160;<xref rid="cas16339-fig-0005" ref-type="fig">5A</xref>). Likewise, GSEA Constellation Map analysis of A group pretreatment versus posttreatment tumors that did not achieve pCR not only revealed significant correlation in previously known cancer genes like <italic toggle="yes">MTOR</italic>, <italic toggle="yes">AKT</italic>, <italic toggle="yes">p53</italic>, and <italic toggle="yes">Cyclin D1</italic>, but also with <italic toggle="yes">BMI1</italic>, <italic toggle="yes">LEF1</italic>, <italic toggle="yes">RELA</italic>, <italic toggle="yes">ATF2</italic>, <italic toggle="yes">MEL18</italic>, and <italic toggle="yes">CRX</italic>, genes with significant AUC and <italic toggle="yes">p</italic> values between the pretreatment and posttreatment tumors in the A group with no pCR achieved (Figure&#160;<xref rid="cas16339-fig-0005" ref-type="fig">5B</xref>). The results from the Constellation Map analysis suggest a potential role of glycan degradation and abovementioned <italic toggle="yes">MTOR</italic>, <italic toggle="yes">AKT</italic>, and other molecules to distinguish HRD&#8208;high tumors treated with paclitaxel and eribulin combined with carboplatin.</p><fig position="float" fig-type="FIGURE" id="cas16339-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Gene Set Enrichment Analysis (GSEA) Constellation Map Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment heatmap of group A triple negative breast cancer tumors. (A) GSEA Constellation Map enrichment heatmap of A1 and A2 posttreatment tumors with area under the curve (AUC), AUC <italic toggle="yes">p</italic> value (AUC.pval), t&#8208;statistic (t&#8208;stat), and t&#8208;statistic <italic toggle="yes">p</italic> value (t.pval) between A1 and A2 posttreatment tumors. Heatmap of differentially enriched KEGG pathway gene sets between A1 (<italic toggle="yes">n</italic>&#8201;=&#8201;5) and A2 (<italic toggle="yes">n</italic>&#8201;=&#8201;8) posttreatment tumors identified glycan degradation as a significantly enriched gene set with AUC.pval of 0.009 and t.pval of 0.006. (B) GSEA Constellation Map enrichment heatmap of group A pre&#8208; and posttreatment tumors with AUC, AUC.pval, t&#8208;stat, and t.pval between the A pre&#8208;and posttreatment tumors. Heatmap of differentially enriched KEGG pathway gene sets between A pretreatment (<italic toggle="yes">n</italic>&#8201;=&#8201;11) and A posttreatment (<italic toggle="yes">n</italic>&#8201;=&#8201;10) tumors identified the top 10 oncogenic signature gene sets with a significant AUC.pval and t&#8208;pval.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="CAS-115-3928-g002.jpg"/></fig></sec><sec id="cas16339-sec-0021"><label>3.8</label><title>Identification of common genes associated with pathological responses in pretreatment tumors from groups A and B</title><p>Next, to identify common genes associated with pathological responses, we used Venn diagram analysis to compare the transcriptomic profiles of pretreatment samples from patients who achieved pCR/quasi&#8208;pCR (QpCR) in both the A and B groups. Only <italic toggle="yes">FGFR2</italic> was found to be common to both prepreatment tumors from patients in group A who achieved pCR and those from patients in group B who achieved QpCR according to FDR&#8201;&lt;0.01 (Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S17</xref>). Upstream regulatory and causal network analysis using the IPA tool suggested different mechanisms of <italic toggle="yes">FGFR2</italic> in A1, A2, and B groups. In pretreatment samples from patients in group A who achieved pCR, IPA predicted the involvement of <italic toggle="yes">NRG2</italic> (a growth factor), a master regulator that inhibits <italic toggle="yes">CSN2</italic>, <italic toggle="yes">DLK1</italic>, <italic toggle="yes">FGFR2</italic>, and <italic toggle="yes">LALBA</italic> through ERBB4, ERK, and RB1 (Tables&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S18</xref> and <xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S19</xref>, Figure&#160;<xref rid="cas16339-fig-0006" ref-type="fig">6A,B</xref>). In pretreatment samples from patients in group B who achieved pCR, a decrease in FGFR2 expression was found to regulate (activate/inhibit) <italic toggle="yes">COL1A1</italic>, <italic toggle="yes">COL3A1</italic>, <italic toggle="yes">KRT1</italic>, and other genes (Figure&#160;<xref rid="cas16339-fig-0006" ref-type="fig">6C,D</xref>). It would be interesting to further analyze how <italic toggle="yes">NRG2</italic> acts as a key regulator of <italic toggle="yes">FGFR2</italic> in the A and B group tumors with pCR to pinpoint its contribution to breast cancer suppression and improved response to microtubule inhibitors in the neoadjuvant setting.</p><fig position="float" fig-type="FIGURE" id="cas16339-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Hierarchical and radial FGFR2 networks in group A and B triple negative breast cancer tumors. (A) Hierarchical FGFR2 network in group A pretreatment tumors from patients who achieved a pathological complete response (pCR), showing FGFR2 as a regulatory protein upstream of DLK1, ERK1/2, CSN2, LALBA, and other proteins. (B) Causal network of NRG2 in group A pretreatment tumors from patients who achieved a pathological complete response. (C) Radial FGFR2 networks consisting of FGFR2 and its interacting partners in group A pretreatment tumors from patients who achieved a pCR. (D) Radial network consisting of FGFR2 and its interacting partners in group B pretreatment tumors from patients who achieved pCR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="CAS-115-3928-g004.jpg"/></fig></sec><sec id="cas16339-sec-0022"><label>3.9</label><title>Multivariate analysis of correlation between clinical parameters and <styled-content style="fixed-case" toggle="no">pCR</styled-content>
</title><p>Multivariate analysis with logistic regression analysis resulted in tumor size and nodal status at presentation significantly correlated with the pCR rate (<italic toggle="yes">p</italic> value: 0.03 and 0.04, respectively). Furthermore, tumor response indicated by MRI (largest tumor diameter&#8201;&lt;50 vs. &#8805;50%), tumor size after initial chemotherapy with PC or EC (&lt;30.5 vs. &#8805;30.5&#8201;mm) and the HRD score (42&#8211;63 vs. &gt;63) were significantly correlated with the pCR rate (<italic toggle="yes">p</italic> values&#8201;=&#8201;0.01, 0.048, and 0.043, respectively) (Table&#160;<xref rid="cas16339-tbl-0003" ref-type="table">3</xref>). Univariate analysis of tumor responses to PC and EC in the two treatment groups (A1 and A2, respectively) showed that the largest tumor diameter (&lt;50 vs. &#8805;50%) was significantly correlated with the response outcome (<italic toggle="yes">p</italic> value&#8201;=&#8201;2.4&#8201;&#215;&#8201;10<sup>&#8722;3</sup>) (Table&#160;<xref rid="cas16339-supitem-0003" ref-type="supplementary-material">S20</xref>).</p><table-wrap position="float" id="cas16339-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Multivariate analysis, relationship with comprehensive pathological complete response as ypT0/is&#8201;+&#8201;ypN0 (<italic toggle="no">N</italic>&#8201;=&#8201;45) in patients with triple negative breast cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Likelihood ratio, &#967;<sup>2</sup>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Odds ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="6" valign="top" rowspan="1">(A) At presentation before starting chemotherapy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment arm: A1 vs. A2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.551</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.2130</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.476</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.2200</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.582&#8211;10.538</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor size: &lt;30.5 vs. &#8805;30.5&#8201;mm</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5.860</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0155</td><td align="char" char="." valign="top" rowspan="1" colspan="1">7.450</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0280</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">1.242&#8211;44.694</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nodal status: N0 vs. N1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.725</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0297</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.171</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0445</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.031&#8211;0.957</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA</italic>m status: t<italic toggle="yes">BRCA2</italic>m vs. t<italic toggle="yes">BRCA1</italic>m</td><td align="char" char="." rowspan="3" valign="top" colspan="1">4.951</td><td align="char" char="." rowspan="3" valign="top" colspan="1">0.0841</td><td align="char" char="." valign="top" rowspan="1" colspan="1">15.526</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0609</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.882&#8211;273.291</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1</italic>m vs. t<italic toggle="yes">BRCA1/2</italic> Negative</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.244</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.1070</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.0439&#8211;1.361</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA2</italic>m vs. t<italic toggle="yes">BRCA1/2</italic> Negative</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.793</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.3070</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.294&#8211;48.878</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HRD status: 42&#8211;63 vs. &gt;&#8201;63</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.485</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0619</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.022</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0740</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.874&#8211;18.508</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">(b) After initial chemotherapy of carboplatin&#8201;+&#8201;paclitaxel or&#8201;+&#8201;eribulin</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment arm: A1 vs. A2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.740</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.3900</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.470</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.395</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.0822&#8211;2.683</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor size: &lt;30.5 vs. &#8805;30.5&#8201;mm</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5.374</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0204</td><td align="char" char="." valign="top" rowspan="1" colspan="1">14.610</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0485</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">1.017&#8211;209.834</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nodal status: N0 vs. N1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.056</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0804</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.177</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.104</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.0219&#8211;1.425</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA</italic>m status: t<italic toggle="yes">BRCA2</italic>m vs. t<italic toggle="yes">BRCA1</italic>m</td><td align="char" char="." rowspan="3" valign="top" colspan="1">2.199</td><td align="char" char="." rowspan="3" valign="top" colspan="1">0.3330</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6.840</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.238</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.280&#8211;166.764</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA1</italic>m vs. t<italic toggle="yes">BRCA1/2</italic>&#8208;negative</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.255</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.189</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.033&#8211;1.961</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t<italic toggle="yes">BRCA2</italic>m vs. t<italic toggle="yes">BRCA1/2</italic>&#8208;negative</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.742</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.698</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">0.106&#8211;28.718</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HRD status: 42&#8211;63 vs. &#8805;63</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5.781</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0162</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11.965</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0431</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">1.084&#8211;132.493</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor response to PC or EC evaluated by MRI: % tumor size in largest diameter&#8201;&#8804;50%, &gt;50%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">13.074</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0003</td><td align="char" char="." valign="top" rowspan="1" colspan="1">95.862</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0115</td><td align="char" char="&#x2013;" valign="top" rowspan="1" colspan="1">2.784&#8211;3300.765</td></tr></tbody></table><table-wrap-foot id="cas16339-ntgp-0003"><fn id="cas16339-note-0004"><p>Abbreviations: CI, confidence interval; EC, eribulin plus carboplatin; HRD, homologous repair deficiency; PC, paclitaxel plus carboplatin; tBRCAm, tumor <italic toggle="yes">BRCA</italic> mutation.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="cas16339-sec-0023"><label>4</label><title>DISCUSSION</title><p>There is a need for more targeted therapies and relevant biological markers associated with treatment responses in TNBC patients. Furthermore, existing treatment methods for TNBC are limited by tumor heterogeneity and poorly understood clinical response or resistance mechanisms. Based on earlier evidence<xref rid="cas16339-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="cas16339-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> on hub and tubulin gene sets, only KLF6 expression was found to be significantly upregulated in tumors treated with eribulin combined with neoadjuvant chemotherapy.</p><p>The pathogenic mutations in <italic toggle="yes">BRCA1</italic> identified in our cohort are located within the functional domains of <italic toggle="yes">BRCA1</italic>,<xref rid="cas16339-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="cas16339-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="cas16339-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> which could lead to treatment resistance in breast cancer.<xref rid="cas16339-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="cas16339-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="cas16339-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Also, irrespective of HRD status, TNBC patients had higher mutation rates in <italic toggle="yes">TP53</italic>. Exploratory analysis to identify commonly altered genes associated with the therapeutic response in the A and B groups identified <italic toggle="yes">FGFR2</italic> as the only gene that was downregulated. The inhibition of NRG2 in pretreatment tumors from patients in group A who achieved pCR (1) was found to regulate ERBB4, ERK, and RB1 inhibition through FGFR2. It is known that the overexpression of FGFR2 and NRG2<xref rid="cas16339-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="cas16339-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="cas16339-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> is associated with poor prognosis and increased cell proliferation. NRG2 activates ERBB4 by binding its promoter region,<xref rid="cas16339-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> which results in the activation of ERBB4, leading to cancer cell proliferation and survival. In this study, both NRG2 and ERBB4 were predicted to be inhibited in pretreatment tumors from patients in group A who achieved pCR. However, although ERBB4 is known to be regulated by NRG2, how it interacts with FGFR2 in tumors is not well understood. FGFR2 was also downregulated in <italic toggle="yes">TP53</italic> and <italic toggle="yes">PIK3CA</italic> mutation&#8208;positive tumors. An earlier report in premenopausal women with sporadic breast cancer found a positive correlation of double <italic toggle="yes">TP53</italic> and <italic toggle="yes">FGFR2</italic> mutation&#8208;positive tumors with decreased breast cancer risk.<xref rid="cas16339-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> A recent report highlighted the role of <italic toggle="yes">FGFR2</italic> in suppressing <italic toggle="yes">BRCA1</italic> through the ERK&#8208;YY1 axis and regulating PD&#8208;L1 to promote tumorigenesis in TNBC.<xref rid="cas16339-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> This study highlights the need to further evaluate the role of FGFR2, and how it interacts with NRG2 and ERBB4 and regulates the pathways leading to cell death in the presence of microtubule inhibitors combined with platinum&#8208;based drugs. Zingg et&#160;al.<xref rid="cas16339-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> reported an enriched coamplification of <italic toggle="yes">FGFR2</italic>/<italic toggle="yes">4</italic>/<italic toggle="yes">19</italic> when the breast tumors had <italic toggle="yes">FGFR2</italic> amplification, <italic toggle="yes">TP53</italic> driver mutations along with <italic toggle="yes">MYC</italic> amplifications, and <italic toggle="yes">PTEN</italic> loss of function alterations. Previously it was also reported in a gastrointestinal cell line study that the inhibition of <italic toggle="yes">FGFR2</italic> signaling can alter the DNA repair mechanism by switching to homologous recombination from nonhomologous end&#8208;joining.<xref rid="cas16339-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> The evidence suggests a possible differential role of <italic toggle="yes">FGFR2</italic> dysregulation in maintaining tumor integrity and DNA repair mechanisms among HRD&#8208;high and &#8208;low tumors in the presence or absence of <italic toggle="yes">TP53</italic> driver mutations.</p><p>The results of GSEA of posttreatment samples from groups A1 and A2 suggest an important role of glycan degradation in the A2 posttreatment tumors. Considering the role proteoglycans or glycolipids play a role in the ECM<xref rid="cas16339-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> and their interactions with integrins,<xref rid="cas16339-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> it would be interesting to further study the role of glycol degradation in TNBC tumors. A more recent study highlights the potential benefits of targeting unregulated sialoglycans and glycoimmune checkpoints in malignant tumors through alpha&#8208;HER2 Ab&#8208;sialidase conjugate, proposing a novel glycoimmune checkpoint therapy technique.<xref rid="cas16339-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> Interestingly, glycan degradation is known to influence cancer cell adhesion and migration. With a positive NMI score and significant <italic toggle="yes">p</italic> value of glycan degradation in our study it is predicted that the glycan degradation could differentiate A1 and A2 posttreatment tumors. These findings suggest a speculative role for glycan degradation in the outcome of eribulin&#8208;containing neoadjuvant treatment.</p><p>The IPA&#8208;predicted activated pathways in posttreatment tumors from group A highlight the role of the tumor microenvironment pathway and regulation of EMT by growth factors pathway, and FAK, IL&#8208;17, and IL&#8208;6 signaling were predicted to be activated. Time&#8208;series blood profiling using 294 blood samples from the JBCRG&#8208;22 clinical trial<xref rid="cas16339-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> revealed a significant correlation between five cytokines and good treatment outcomes through enhancement of the immune response.<xref rid="cas16339-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> This supports the use of transcriptional profiles of the cytokine markers found in this study and could be used to validate their use as response predictive markers in future studies. Our findings involving tumor size as a predictor of the pathological response concurs with earlier reports. Tumor size is a known predictor of the response to neoadjuvant chemotherapy.<xref rid="cas16339-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="cas16339-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</p><p>Overall, our study results suggest potential markers like mutations in <italic toggle="yes">TP53</italic> and <italic toggle="yes">KMT2C</italic>, t<italic toggle="yes">BRCA</italic>m in HRD&#8208;high tumors in tumors with higher pCR rates, and mutations in <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">HRAS</italic> in tumors with lower pCR rates. We hypothesize that the downregulation of FGFR2 in <italic toggle="yes">TP53</italic> mutation&#8208;positive tumors achieving pCR in the HRD&#8208;high group could be a response marker. The role of MAP6, MAP7D1, and MAP7D2 could be speculative as response markers towards MTIs in combination with carboplatin. When differentiating A1 versus A2 tumors, we postulate that glycan degradation could be an interesting biological process to study in TNBC individuals.</p><p>A limitation of this study was the use of a small sample size, although a prospective design was analyzed. As the results have not been validated, the use of the HRD score, <italic toggle="yes">TP53</italic>, t<italic toggle="yes">BRCA</italic>m, <italic toggle="yes">PIK3CA</italic>, and <italic toggle="yes">KMT2C</italic> mutation status, together with clinicopathologic parameters and the enriched gene sets reported in this study could serve as preliminary findings contributing to future studies.</p><p>In conclusion, we speculated on the use of HRD score, <italic toggle="yes">TP53</italic>, <italic toggle="yes">KMT2C</italic>, and <italic toggle="yes">PIK3CA</italic> mutational status, and FGFR2 expression as response markers in TNBC. Further investigations are needed to understand the role of the HRD score, <italic toggle="yes">TP53</italic> mutational status, <italic toggle="yes">FGFR2</italic> regulation, and the function of microtubule genes and glycan degradation, to improve pCR prediction and chemoresistance when using microtubule inhibitors.</p></sec><sec id="cas16339-sec-0028"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Tomomi Nishimura:</bold> Conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; software; validation; visualization; writing &#8211; original draft; writing &#8211; review and editing. <bold>Ravi Velaga:</bold> Conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; software; validation; visualization; writing &#8211; original draft; writing &#8211; review and editing. <bold>Norikazu Masuda:</bold> Conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; software; supervision; validation; visualization; writing &#8211; original draft; writing &#8211; review and editing. <bold>Kosuke Kawaguchi:</bold> Conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; software; validation; visualization. <bold>Shuji Kawaguchi:</bold> Conceptualization; data curation; formal analysis; investigation; methodology; software; validation; visualization. <bold>Masahiro Takada:</bold> Resources. <bold>Yurina Maeshima:</bold> Data curation; methodology; resources. <bold>Sunao Tanaka:</bold> Data curation; methodology; project administration; resources; writing &#8211; review and editing. <bold>Yuichiro Kikawa:</bold> Data curation; resources; writing &#8211; review and editing. <bold>Takayuki Kadoya:</bold> Resources; writing &#8211; review and editing. <bold>Hiroko Bando:</bold> Resources; writing &#8211; review and editing. <bold>Rikiya Nakamura:</bold> Resources; writing &#8211; review and editing. <bold>Yutaka Yamamoto:</bold> Resources; writing &#8211; review and editing. <bold>Takayuki Ueno:</bold> Resources; writing &#8211; review and editing. <bold>Hiroyuki Yasojima:</bold> Resources; writing &#8211; review and editing. <bold>Hiroshi Ishiguro:</bold> Resources; writing &#8211; review and editing. <bold>Satoshi Morita:</bold> Data curation; formal analysis; methodology; resources; supervision; validation; visualization; writing &#8211; review and editing. <bold>Shinji Ohno:</bold> Conceptualization; resources; writing &#8211; review and editing. <bold>Hironori Haga:</bold> Resources; writing &#8211; review and editing. <bold>Fumihiko Matsuda:</bold> Conceptualization; supervision; visualization; writing &#8211; review and editing. <bold>Seishi Ogawa:</bold> Conceptualization; formal analysis; investigation; methodology; software; supervision; validation; visualization; writing &#8211; review and editing. <bold>Masakazu Toi:</bold> Conceptualization; data curation; formal analysis; funding acquisition; investigation; methodology; project administration; resources; software; supervision; validation; visualization; writing &#8211; original draft; writing &#8211; review and editing.</p></sec><sec sec-type="COI-statement" id="cas16339-sec-0025"><title>CONFLICT OF INTEREST STATEMENT</title><p>SO, SOg, and MT are editorial board members of <italic toggle="yes">Cancer Science</italic>. Annual profit from shares is received by SOg from Asahi Genomics Co., Ltd. Total annual value of lecture fees, honoraria, or other fees paid by a single company or for&#8208;profit organization for the time or labor of a researcher engaged for conference attendance is received by: NM from Chugai, Pfizer, Astra Zeneca (AZ), Eli Lilly (EL), Daiichi Sankyo (DS), and Eisai; KoK from Eisai, Chugai, and Takeda; MTa from Yakult, DS, AZ, Kyoto Breast Cancer Research Network (KBCRN), and JBCRG; YK from Eisai, Novartis, Pfizer, EL, Taiho, and Chugai; HB from Chugai and Eisai; RN from EL, AZ, DS, Chugai, Eisai, and Novartis; YY from AZ, Chugai, and MSD; TU from Chugai, Eisai, AZ, and Novartis; SM from AZ, Bristol&#8208;Myers Squibb (BMS), Chugai, Eisai, EL, MSD, Pfizer, Taiho, and Novartis; SO from MSD, Lilly, Nippon Kayaku (NK), and Chugai; and MT from BERTIS, Inc., Kansai&#8208;Med net, EL (KMN), Pfizer, DS, Terumo, Pfizer, and AZ. Total annual value of research funds (joint research funds, contract research funds, clinical trial funds, etc.) is received by: NM from Chugai, EL, AZ, Pfizer, DS, MSD, Eisai, Novartis, Sanofi, and Kyowa&#8208;Kirin (KyK); NK from Ono&#8208;Pharma; KK from TERUMO, Astellas, EL, and KBCRN; MTa from Yakult, DS, AZ, KBCRN, and JBCRG; YY from Chugai and KyK; TU from Lilly; HI from Nipro, Eisai, DS, Chugai, Takeda, and AZ; SM from Eisai; SO from Eisai and Taiho; and MT from TERUMO, Astellas, EL, KBCRN, JBCRG, Yakult, Zene, KMN, Shimazu, AFI, Taiho, and Sanwa&#8208;Syurui. Total annual value of scholarship (incentive) endowments provided directly from a single company or for&#8208;profit organization, or research grants provided directly from a private academic support organization is received by MT from Eisai, Chugai, KyK, and NK. SOg declares an endowed chair etc. funded by a company or for&#8208;profit organization, or has accepted a researcher, etc. from a company or for&#8208;profit organization where the declarer is a research facility representative from Chordia Therapeutics Inc., Nanpuh Hospital. The other authors declare no conflicts of interest.</p></sec><sec id="cas16339-sec-0027"><title>DISCLOSURES</title><p>Eisai Co., Ltd provided drugs used in the JBCRG&#8208;22 clinical trial and funded this translational research.</p></sec><sec id="cas16339-sec-0026"><title>ETHICS STATEMENT</title><p>Approval of the research protocol by an institutional review board: The Kyoto University Graduate School of Medicine ethical committee approved this study.</p><p>Informed consent: Informed consent was obtained from all study participants.</p><p>Registry and the registration no. of the study/trial: N/A.</p><p>Animal studies: N/A.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cas16339-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Appendix S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-115-3928-s001.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas16339-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-115-3928-s003.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas16339-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table&#160;S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-115-3928-s002.xlsx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="cas16339-sec-0024"><title>ACKNOWLEDGMENTS</title><p>This study was sponsored by the association of JBCRG and Eisai Co., Ltd. We would also like to thank all the translational research study participants.</p></ack><ref-list content-type="cited-references" id="cas16339-bibl-0001"><title>REFERENCES</title><ref id="cas16339-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cas16339-cit-0001"><string-name name-style="western"><surname>Tutt</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tovey</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cheang</surname><given-names>MCU</given-names></string-name>, et&#160;al. <article-title>Carboplatin in BRCA1/2&#8208;mutated and triple&#8208;negative breast cancer BRCAness subgroups: the TNT trial</article-title>. <source>Nat Med</source>. <year>2018</year>;<volume>5</volume>:<fpage>628</fpage>&#8208;<lpage>637</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-018-0009-7</pub-id><pub-id pub-id-type="pmcid">PMC6372067</pub-id><pub-id pub-id-type="pmid">29713086</pub-id></mixed-citation></ref><ref id="cas16339-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cas16339-cit-0002"><string-name name-style="western"><surname>Zhao</surname><given-names>EY</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Pleasance</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Homologous recombination deficiency and platinum&#8208;based therapy outcomes in advanced breast cancer</article-title>. <source>Clin Cancer Res</source>. <year>2017</year>;<volume>23</volume>(<issue>24</issue>):<fpage>7521</fpage>&#8208;<lpage>7530</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-1941</pub-id><pub-id pub-id-type="pmid">29246904</pub-id></mixed-citation></ref><ref id="cas16339-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cas16339-cit-0003"><string-name name-style="western"><surname>Lehmann</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Bauer</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Identification of human triple&#8208;negative breast cancer subtypes and preclinical models for selection of targeted therapies</article-title>. <source>J Clin Invest</source>. <year>2011</year>;<volume>121</volume>(<issue>7</issue>):<fpage>2750</fpage>&#8208;<lpage>2767</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI45014</pub-id><pub-id pub-id-type="pmid">21633166</pub-id><pub-id pub-id-type="pmcid">PMC3127435</pub-id></mixed-citation></ref><ref id="cas16339-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cas16339-cit-0004"><string-name name-style="western"><surname>Craig</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>O'Shaughnessy</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Kiefer</surname><given-names>JA</given-names></string-name>, et&#160;al. <article-title>Genome and transcriptome sequencing in prospective metastatic triple&#8208;negative breast cancer uncovers therapeutic vulnerabilities</article-title>. <source>Mol Cancer Ther</source>. <year>2013</year>;<volume>12</volume>(<issue>1</issue>):<fpage>104</fpage>&#8208;<lpage>116</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0781</pub-id><pub-id pub-id-type="pmid">23171949</pub-id></mixed-citation></ref><ref id="cas16339-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cas16339-cit-0005"><string-name name-style="western"><surname>Jiang</surname><given-names>YZ</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Suo</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Genomic and transcriptomic landscape of triple&#8208;negative breast cancers: subtypes and treatment strategies</article-title>. <source>Cancer Cell</source>. <year>2019</year>;<volume>35</volume>(<issue>3</issue>):<fpage>428</fpage>&#8208;<lpage>440.e5</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccell.2019.02.001</pub-id><pub-id pub-id-type="pmid">30853353</pub-id></mixed-citation></ref><ref id="cas16339-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cas16339-cit-0006"><string-name name-style="western"><surname>Masuda</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bando</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yamanaka</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Eribulin&#8208;based neoadjuvant chemotherapy for triple&#8208;negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial</article-title>. <source>Breast Cancer Res Treat</source>. <year>2021</year>;<volume>188</volume>(<issue>1</issue>):<fpage>117</fpage>&#8208;<lpage>131</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-021-06184-w</pub-id><pub-id pub-id-type="pmid">33763789</pub-id><pub-id pub-id-type="pmcid">PMC8233289</pub-id></mixed-citation></ref><ref id="cas16339-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cas16339-cit-0007"><string-name name-style="western"><surname>Dezs&#337;</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Oestreicher</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>8</issue>):<elocation-id>e106131</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0106131</pub-id><pub-id pub-id-type="pmid">25171249</pub-id><pub-id pub-id-type="pmcid">PMC4149521</pub-id></mixed-citation></ref><ref id="cas16339-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cas16339-cit-0008"><string-name name-style="western"><surname>Qin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YH</given-names></string-name>. <article-title>Molecular&#8208;level effects of eribulin and paclitaxel on breast cancer based on differential co&#8208;expression network analysis</article-title>. <source>Genet Mol Res</source>. <year>2016</year>;<volume>15</volume>(<issue>2</issue>). doi:<pub-id pub-id-type="doi">10.4238/gmr.15028192</pub-id><pub-id pub-id-type="pmid">27420999</pub-id></mixed-citation></ref><ref id="cas16339-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cas16339-cit-0009"><string-name name-style="western"><surname>Ueno</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kitano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Masuda</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple&#8208;negative breast cancer: Japan breast cancer research group (JBCRG)22 TR</article-title>. <source>BMC Med</source>. <year>2022</year>;<volume>20</volume>(<issue>1</issue>):<fpage>136</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12916-022-02332-1</pub-id><pub-id pub-id-type="pmid">35462552</pub-id><pub-id pub-id-type="pmcid">PMC9036790</pub-id></mixed-citation></ref><ref id="cas16339-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cas16339-cit-0010"><string-name name-style="western"><surname>Timms</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Abkevich</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Hughes</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes</article-title>. <source>Breast Cancer Res</source>. <year>2014</year>;<volume>16</volume>(<issue>6</issue>):<fpage>475</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13058-014-0475-x</pub-id><pub-id pub-id-type="pmid">25475740</pub-id><pub-id pub-id-type="pmcid">PMC4308910</pub-id></mixed-citation></ref><ref id="cas16339-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cas16339-cit-0011"><string-name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sanada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shiraishi</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Frequent pathway mutations of splicing machinery in myelodysplasia</article-title>. <source>Nature</source>. <year>2011</year>;<volume>478</volume>(<issue>7367</issue>):<fpage>64</fpage>&#8208;<lpage>69</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature10496</pub-id><pub-id pub-id-type="pmid">21909114</pub-id></mixed-citation></ref><ref id="cas16339-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cas16339-cit-0012"><string-name name-style="western"><surname>Inagaki&#8208;Kawata</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kawaguchi&#8208;Sakita</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants</article-title>. <source>Commun Biol</source>. <year>2020</year>;<volume>3</volume>(<issue>1</issue>):<fpage>578</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s42003-020-01301-9</pub-id><pub-id pub-id-type="pmid">33067557</pub-id><pub-id pub-id-type="pmcid">PMC7567851</pub-id></mixed-citation></ref><ref id="cas16339-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cas16339-cit-0013"><string-name name-style="western"><surname>Nik&#8208;Zainal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Staaf</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Landscape of somatic mutations in 560 breast cancer whole&#8208;genome sequences</article-title>. <source>Nature</source>. <year>2016</year>;<volume>534</volume>(<issue>7605</issue>):<fpage>47</fpage>&#8208;<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature17676</pub-id> Erratum in: Nature 2019;566(7742):E1.<pub-id pub-id-type="pmid">27135926</pub-id><pub-id pub-id-type="pmcid">PMC4910866</pub-id></mixed-citation></ref><ref id="cas16339-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="cas16339-cit-0014"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link></mixed-citation></ref><ref id="cas16339-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cas16339-cit-0015"><string-name name-style="western"><surname>Pritchard</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Mateo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>MF</given-names></string-name>, et&#160;al. <article-title>Inherited DNA&#8208;repair gene mutations in men with metastatic prostate cancer</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>(<issue>5</issue>):<fpage>443</fpage>&#8208;<lpage>453</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1603144</pub-id><pub-id pub-id-type="pmid">27433846</pub-id><pub-id pub-id-type="pmcid">PMC4986616</pub-id></mixed-citation></ref><ref id="cas16339-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cas16339-cit-0016"><string-name name-style="western"><surname>Bolger</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Lohse</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Usadel</surname><given-names>B</given-names></string-name>. <article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>(<issue>15</issue>):<fpage>2114</fpage>&#8208;<lpage>2120</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id><pub-id pub-id-type="pmcid">PMC4103590</pub-id></mixed-citation></ref><ref id="cas16339-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cas16339-cit-0017"><string-name name-style="western"><surname>Vera Alvarez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pongor</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Mari&#241;o&#8208;Ram&#237;rez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Landsman</surname><given-names>D</given-names></string-name>. <article-title>TPMCalculator: one&#8208;step software to quantify mRNA abundance of genomic features</article-title>. <source>Bioinformatics</source>. <year>2019</year>;<volume>35</volume>(<issue>11</issue>):<fpage>1960</fpage>&#8208;<lpage>1962</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/bty896</pub-id><pub-id pub-id-type="pmid">30379987</pub-id><pub-id pub-id-type="pmcid">PMC6546121</pub-id></mixed-citation></ref><ref id="cas16339-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="cas16339-cit-0018"><article-title>QIAGEN CLC Genomics Workbench 20.0.2</article-title>. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://digitalinsights.qiagen.com/" ext-link-type="uri">https://digitalinsights.qiagen.com/</ext-link>)</mixed-citation></ref><ref id="cas16339-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cas16339-cit-0019"><string-name name-style="western"><surname>Benjamini</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hochberg</surname><given-names>Y</given-names></string-name>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J R Stat</source>. <year>1995</year>;<volume>57</volume>(<issue>1</issue>):<fpage>289</fpage>&#8208;<lpage>300</lpage>.</mixed-citation></ref><ref id="cas16339-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cas16339-cit-0020"><string-name name-style="western"><surname>Subramanian</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tamayo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mootha</surname><given-names>VK</given-names></string-name>, et&#160;al. <article-title>Gene set enrichment analysis: a knowledge&#8208;based approach for interpreting genome&#8208;wide expression profiles</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2005</year>;<volume>102</volume>(<issue>43</issue>):<fpage>15545</fpage>&#8208;<lpage>15550</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id><pub-id pub-id-type="pmcid">PMC1239896</pub-id></mixed-citation></ref><ref id="cas16339-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cas16339-cit-0021"><string-name name-style="western"><surname>Tan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Tamayo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Haining</surname><given-names>WN</given-names></string-name>, <string-name name-style="western"><surname>Mesirov</surname><given-names>JP</given-names></string-name>. <article-title>Constellation map: downstream visualization and interpretation of gene set enrichment results</article-title>. <source>F1000Res</source>. <year>2015</year>;<volume>4</volume>:<fpage>167</fpage>. doi:<pub-id pub-id-type="doi">10.12688/f1000research.6644.1</pub-id><pub-id pub-id-type="pmid">26594333</pub-id><pub-id pub-id-type="pmcid">PMC4648224</pub-id></mixed-citation></ref><ref id="cas16339-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cas16339-cit-0022"><string-name name-style="western"><surname>Kr&#228;mer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Green</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pollard</surname><given-names>J</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Tugendreich</surname><given-names>S</given-names></string-name>. <article-title>Causal analysis approaches in ingenuity pathway analysis</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>(<issue>4</issue>):<fpage>523</fpage>&#8208;<lpage>530</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btt703</pub-id><pub-id pub-id-type="pmid">24336805</pub-id><pub-id pub-id-type="pmcid">PMC3928520</pub-id></mixed-citation></ref><ref id="cas16339-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cas16339-cit-0023"><string-name name-style="western"><surname>Zingg</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bhin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yemelyanenko</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Truncated FGFR2 is a clinically actionable oncogene in multiple cancers</article-title>. <source>Nature</source>. <year>2022</year>;<volume>608</volume>(<issue>7923</issue>):<fpage>609</fpage>&#8208;<lpage>617</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-022-05066-5</pub-id> Erratum in: Nature 2022;609(7929):E13.<pub-id pub-id-type="pmid">35948633</pub-id><pub-id pub-id-type="pmcid">PMC9436779</pub-id></mixed-citation></ref><ref id="cas16339-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cas16339-cit-0024"><string-name name-style="western"><surname>Jensen</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Proctor</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Marquis</surname><given-names>ST</given-names></string-name>, et&#160;al. <article-title>BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1&#8208;mediated cell growth suppression</article-title>. <source>Oncogene</source>. <year>1998</year>;<volume>16</volume>(<issue>9</issue>):<fpage>1097</fpage>&#8208;<lpage>1112</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.onc.1201861</pub-id><pub-id pub-id-type="pmid">9528852</pub-id></mixed-citation></ref><ref id="cas16339-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cas16339-cit-0025"><string-name name-style="western"><surname>Bermudez</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Pag&#232;s</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gimond</surname><given-names>C</given-names></string-name>. <article-title>The dual&#8208;specificity MAP kinase phosphatases: critical roles in development and cancer</article-title>. <source>Am J Physiol Cell Physiol</source>. <year>2010</year>;<volume>299</volume>(<issue>2</issue>):<fpage>C189</fpage>&#8208;<lpage>C202</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajpcell.00347.2009</pub-id><pub-id pub-id-type="pmid">20463170</pub-id></mixed-citation></ref><ref id="cas16339-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cas16339-cit-0026"><string-name name-style="western"><surname>Yoshida</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Watanabe</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yokoyama</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X</article-title>. <source>Oncotarget</source>. <year>2019</year>;<volume>10</volume>(<issue>35</issue>):<fpage>3276</fpage>&#8208;<lpage>3284</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.26852</pub-id><pub-id pub-id-type="pmid">31143373</pub-id><pub-id pub-id-type="pmcid">PMC6524931</pub-id></mixed-citation></ref><ref id="cas16339-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cas16339-cit-0027"><string-name name-style="western"><surname>Nishikawa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Koike</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>BRCA1&#8208;associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>(<issue>1</issue>):<fpage>111</fpage>&#8208;<lpage>119</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3355</pub-id><pub-id pub-id-type="pmid">19117993</pub-id></mixed-citation></ref><ref id="cas16339-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cas16339-cit-0028"><string-name name-style="western"><surname>Atipairin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ratanaphan</surname><given-names>A</given-names></string-name>. <article-title>In vitro enhanced sensitivity to cisplatin in D67Y BRCA1 RING domain protein</article-title>. <source>Breast Cancer (Auckl)</source>. <year>2011</year>;<volume>5</volume>:<fpage>201</fpage>&#8208;<lpage>208</lpage>. doi:<pub-id pub-id-type="doi">10.4137/BCBCR.S8184</pub-id><pub-id pub-id-type="pmid">22084573</pub-id><pub-id pub-id-type="pmcid">PMC3201098</pub-id></mixed-citation></ref><ref id="cas16339-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cas16339-cit-0029"><string-name name-style="western"><surname>Drost</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bouwman</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rottenberg</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance</article-title>. <source>Cancer Cell</source>. <year>2011</year>;<volume>20</volume>(<issue>6</issue>):<fpage>797</fpage>&#8208;<lpage>809</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccr.2011.11.014</pub-id><pub-id pub-id-type="pmid">22172724</pub-id></mixed-citation></ref><ref id="cas16339-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cas16339-cit-0030"><string-name name-style="western"><surname>Zhao</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>GY</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>WW</given-names></string-name>. <article-title>Integrative analysis of neuregulin family members&#8208;related tumor microenvironment for predicting the prognosis in gliomas</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>682415</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2021.682415</pub-id><pub-id pub-id-type="pmid">34054873</pub-id><pub-id pub-id-type="pmcid">PMC8155525</pub-id></mixed-citation></ref><ref id="cas16339-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cas16339-cit-0031"><string-name name-style="western"><surname>Carraway</surname><given-names>KL</given-names><suffix>3rd</suffix></string-name>, <string-name name-style="western"><surname>Weber</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Unger</surname><given-names>MJ</given-names></string-name>, et&#160;al. <article-title>Neuregulin&#8208;2, a new ligand of ErbB3/ErbB4&#8208;receptor tyrosine kinases</article-title>. <source>Nature</source>. <year>1997</year>;<volume>387</volume>(<issue>6632</issue>):<fpage>512</fpage>&#8208;<lpage>516</lpage>. doi:<pub-id pub-id-type="doi">10.1038/387512a0</pub-id><pub-id pub-id-type="pmid">9168115</pub-id></mixed-citation></ref><ref id="cas16339-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cas16339-cit-0032"><string-name name-style="western"><surname>DeAngelis</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tollefsbol</surname><given-names>TO</given-names></string-name>. <article-title>2D difference gel electrophoresis analysis of different time points during the course of neoplastic transformation of human mammary epithelial cells</article-title>. <source>J Proteome Res</source>. <year>2011</year>;<volume>10</volume>(<issue>2</issue>):<fpage>447</fpage>&#8208;<lpage>458</lpage>. doi:<pub-id pub-id-type="doi">10.1021/pr100533k</pub-id><pub-id pub-id-type="pmid">21105747</pub-id><pub-id pub-id-type="pmcid">PMC3390236</pub-id></mixed-citation></ref><ref id="cas16339-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cas16339-cit-0033"><string-name name-style="western"><surname>Cherdyntseva</surname><given-names>NV</given-names></string-name>, <string-name name-style="western"><surname>Denisov</surname><given-names>EV</given-names></string-name>, <string-name name-style="western"><surname>Litviakov</surname><given-names>NV</given-names></string-name>, et&#160;al. <article-title>Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis</article-title>. <source>DNA Cell Biol</source>. <year>2012</year>;<volume>31</volume>(<issue>3</issue>):<fpage>306</fpage>&#8208;<lpage>316</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dna.2011.1351</pub-id><pub-id pub-id-type="pmid">21838531</pub-id></mixed-citation></ref><ref id="cas16339-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cas16339-cit-0034"><string-name name-style="western"><surname>Lei</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Activation of FGFR2 signaling suppresses BRCA1 and drives triple&#8208;negative mammary tumorigenesis that is sensitive to immunotherapy</article-title>. <source>Adv Sci (Weinh)</source>. <year>2021</year>;<volume>8</volume>(<issue>21</issue>):<elocation-id>e2100974</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/advs.202100974</pub-id><pub-id pub-id-type="pmid">34514747</pub-id><pub-id pub-id-type="pmcid">PMC8564435</pub-id></mixed-citation></ref><ref id="cas16339-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cas16339-cit-0035"><string-name name-style="western"><surname>Sergei</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Pavel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Aigul</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Inhibition of FGFR2&#8208;signaling attenuates a homology&#8208;mediated DNA repair in GIST and sensitizes them to DNA&#8208;topoisomerase II inhibitors</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>1</issue>):<elocation-id>352</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/ijms21010352</pub-id><pub-id pub-id-type="pmid">31948066</pub-id><pub-id pub-id-type="pmcid">PMC6982350</pub-id></mixed-citation></ref><ref id="cas16339-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cas16339-cit-0036"><string-name name-style="western"><surname>Piperigkou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Mohr</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Karamanos</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>G&#246;tte</surname><given-names>M</given-names></string-name>. <article-title>Shed proteoglycans in tumor stroma</article-title>. <source>Cell Tissue Res</source>. <year>2016</year>;<volume>365</volume>(<issue>3</issue>):<fpage>643</fpage>&#8208;<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00441-016-2452-4</pub-id><pub-id pub-id-type="pmid">27365088</pub-id></mixed-citation></ref><ref id="cas16339-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cas16339-cit-0037"><string-name name-style="western"><surname>Hynes</surname><given-names>RO</given-names></string-name>. <article-title>Integrins: bidirectional, allosteric signaling machines</article-title>. <source>Cell</source>. <year>2002</year>;<volume>110</volume>(<issue>6</issue>):<fpage>673</fpage>&#8208;<lpage>687</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0092-8674(02)00971-6</pub-id><pub-id pub-id-type="pmid">12297042</pub-id></mixed-citation></ref><ref id="cas16339-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cas16339-cit-0038"><string-name name-style="western"><surname>Gray</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Stanczak</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Mantuano</surname><given-names>NR</given-names></string-name>, et&#160;al. <article-title>Targeted glycan degradation potentiates the anticancer immune response in&#160;vivo</article-title>. <source>Nat Chem Biol</source>. <year>2020</year>;<volume>16</volume>(<issue>12</issue>):<fpage>1376</fpage>&#8208;<lpage>1384</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41589-020-0622-x</pub-id><pub-id pub-id-type="pmid">32807964</pub-id><pub-id pub-id-type="pmcid">PMC7727925</pub-id></mixed-citation></ref><ref id="cas16339-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cas16339-cit-0039"><string-name name-style="western"><surname>Saldajeno</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Kawaoka</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Masuda</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Time&#8208;series blood cytokine profiles correlate with treatment responses in triple&#8208;negative breast cancer patients</article-title>. <source>Br J Cancer</source>. <year>2024</year>;<volume>130</volume>:<fpage>1023</fpage>&#8208;<lpage>1035</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41416-023-02527-0</pub-id><pub-id pub-id-type="pmid">38238427</pub-id><pub-id pub-id-type="pmcid">PMC10951271</pub-id></mixed-citation></ref><ref id="cas16339-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cas16339-cit-0040"><string-name name-style="western"><surname>Goorts</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dreuning</surname><given-names>KMA</given-names></string-name>, <string-name name-style="western"><surname>Houwers</surname><given-names>JB</given-names></string-name>, et&#160;al. <article-title>MRI&#8208;based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer</article-title>. <source>Breast Cancer Res</source>. <year>2018</year>;<volume>20</volume>(<issue>1</issue>):<fpage>34</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13058-018-0950-x</pub-id><pub-id pub-id-type="pmid">29669584</pub-id><pub-id pub-id-type="pmcid">PMC5907188</pub-id></mixed-citation></ref><ref id="cas16339-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cas16339-cit-0041"><string-name name-style="western"><surname>Livingston&#8208;Rosanoff</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Schumacher</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vande Walle</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Does tumor size predict response to neoadjuvant chemotherapy in the modern era of biologically driven treatment? A Nationwide study of US breast cancer patients</article-title>. <source>Clin Breast Cancer</source>. <year>2019</year>;<volume>19</volume>(<issue>6</issue>):<fpage>e741</fpage>&#8208;<lpage>e747</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clbc.2019.05.014</pub-id><pub-id pub-id-type="pmid">31300338</pub-id><pub-id pub-id-type="pmcid">PMC6888946</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>